<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="sps-1.9" dtd-version="1.1" xml:lang="pt" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
        <publisher-loc>S&#227;o Paulo, SP, Brazil</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v3">fvDZBJVCnTL8yg7qWzfTGng</article-id>
      <article-id pub-id-type="other">00011</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v2">S0066-782X2009000300011</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v1">S0066-782X(09)09200311</article-id>
      <article-id pub-id-type="doi">10.1590/S0066-782X2009000300011</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Artigos Originais</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Avalia&#231;&#227;o do pept&#237;deo natriur&#233;tico tipo B no diagn&#243;stico de rejei&#231;&#227;o ap&#243;s transplante card&#237;aco pedi&#225;trico</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Sylos</surname>
            <given-names>Cristina de</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Azeka</surname>
            <given-names>Estela</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kajita</surname>
            <given-names>Luis</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Benvenutti</surname>
            <given-names>Luis</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Strunz</surname>
            <given-names>C&#233;lia Cassaro</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Branco</surname>
            <given-names>Kl&#233;bia Castello</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Riso</surname>
            <given-names>Arlindo Almeida</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tanamati</surname>
            <given-names>Carla</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Jatene</surname>
            <given-names>Marcelo</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Barbero-Marcial</surname>
            <given-names>Miguel</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
      </contrib-group>
      <aff id="aff01">
        <addr-line>
          <named-content content-type="city">S&#227;o Paulo</named-content>
          <named-content content-type="state">S&#227;o Paulo</named-content>
        </addr-line>
        <institution content-type="orgname">Universidade de S&#227;o Paulo</institution>
        <institution content-type="orgdiv1">Faculdade de Medicina </institution>
        <institution content-type="orgdiv2">Hospital das Cl&#237;nicas</institution>
        <country country="BR">Brazil</country>
      </aff>
      <pub-date date-type="collection" publication-format="electronic">
        <month>03</month>
        <year>2009</year>
      </pub-date>
      <volume>92</volume>
      <issue>3</issue>
      <fpage>227</fpage>
      <lpage>232</lpage>
      <history>
        <date date-type="accepted">
          <day>31</day>
          <month>07</month>
          <year>2008</year>
        </date>
        <date date-type="rev-recd">
          <day>04</day>
          <month>07</month>
          <year>2008</year>
        </date>
        <date date-type="received">
          <day>11</day>
          <month>04</month>
          <year>2008</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/" xml:lang="en">
          <license-p>This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>FUNDAMENTO: A rejei&#231;&#227;o constitui-se em uma das principais causas de mortalidade ap&#243;s o transplante card&#237;aco pedi&#225;trico. O pept&#237;deo natriur&#233;tico tipo B (BNP) tem sido estudado como m&#233;todo no diagn&#243;stico de rejei&#231;&#227;o aguda, especialmente em pacientes adultos submetidos a transplante card&#237;aco. OBJETIVO:Correlacionar o n&#237;vel s&#233;rico de BNP &#224; rejei&#231;&#227;o aguda diagnosticada pela bi&#243;psia endomioc&#225;rdica em pacientes do grupo de transplante card&#237;aco pedi&#225;trico. M&#201;TODOS:Foram coletadas 50 amostras de BNP de 33 crian&#231;as em p&#243;s-operat&#243;rio de transplante card&#237;aco e analisados dados de idade, sexo, cor, grupo sang&#252;&#237;neo, painel imunol&#243;gico, tempo de evolu&#231;&#227;o ap&#243;s o transplante, classe funcional, imunossupress&#227;o utilizada e n&#250;mero de rejei&#231;&#245;es. RESULTADOS:Foram 33 crian&#231;as com idade mediana de 10,13 anos, predom&#237;nio do sexo feminino (54%) e da cor branca (78%). No momento da dosagem de BNP o tempo m&#233;dio de transplante foi 4,25 anos. A bi&#243;psia endomioc&#225;rdica diagnosticou nove rejei&#231;&#245;es em oito pacientes (27%), sendo tr&#234;s com grau 3 A, cinco com grau 2 e um com rejei&#231;&#227;o humoral. No momento da bi&#243;psia, a maioria dos pacientes encontrava-se assintom&#225;tica. O n&#237;vel s&#233;rico de BNP foi em m&#233;dia 77,18 pg/ml, sendo 144,22 pg/ml no grupo com rejei&#231;&#227;o e 62,46 pg/ml no grupo sem rejei&#231;&#227;o, com p = 0,02. CONCLUS&#195;O: Crian&#231;as assintom&#225;ticas podem apresentar rejei&#231;&#227;o aguda no p&#243;s-operat&#243;rio de transplante card&#237;aco. O n&#237;vel s&#233;rico de BNP apresentou diferen&#231;a estatisticamente significante no grupo com rejei&#231;&#227;o, podendo ser m&#233;todo adicional no diagn&#243;stico de rejei&#231;&#227;o card&#237;aca.</p>
      </abstract>
      <kwd-group xml:lang="pt" kwd-group-type="author-generated">
        <kwd>Transplante de cora&#231;&#227;o</kwd>
        <kwd>rejei&#231;&#227;o do enxerto</kwd>
        <kwd>pept&#237;deo natriur&#233;tico tipo B</kwd>
        <kwd>bi&#243;psia</kwd>
        <kwd>crian&#231;as</kwd>
      </kwd-group>
      <pub-date publication-format="electronic" date-type="pub">
        <day>17</day>
        <month>04</month>
        <year>2009</year>
      </pub-date>
    </article-meta>
  </front>
  <body>
    <p>ARTIGO ORIGINAL </p>
    <p> TRANSPLANTE CARD&#205;ACO - CL&#205;NICO</p>
    <p>
      <bold>Avalia&#231;&#227;o do pept&#237;deo natriur&#233;tico tipo B no diagn&#243;stico de rejei&#231;&#227;o ap&#243;s transplante card&#237;aco pedi&#225;trico</bold>
    </p>
    <p>
      <bold>Cristina de Sylos; Estela Azeka; Luis Kajita; Luis Benvenutti; C&#233;lia Cassaro Strunz; Kl&#233;bia Castello Branco; Arlindo Almeida Riso; Carla Tanamati; Marcelo Jatene; Miguel Barbero-Marcial</bold>
    </p>
    <p>Instituto do Cora&#231;&#227;o (InCor) do Hospital das Cl&#237;nicas da Faculdade de Medicina Universidade de S&#227;o Paulo (HCFMUSP), S&#227;o Paulo, SP - Brasil</p>
    <p>
      <xref ref-type="corresp" rid="back">Correspond&#234;ncia</xref>
    </p>
    <p>
      <bold>RESUMO</bold>
    </p>
    <p><bold>FUNDAMENTO:</bold> A rejei&#231;&#227;o constitui-se em uma das principais causas de mortalidade ap&#243;s o transplante card&#237;aco pedi&#225;trico. O pept&#237;deo natriur&#233;tico tipo B (BNP) tem sido estudado como m&#233;todo no diagn&#243;stico de rejei&#231;&#227;o aguda, especialmente em pacientes adultos submetidos a transplante card&#237;aco. </p>
    <p><bold>OBJETIVO:</bold>Correlacionar o n&#237;vel s&#233;rico de BNP &#224; rejei&#231;&#227;o aguda diagnosticada pela bi&#243;psia endomioc&#225;rdica em pacientes do grupo de transplante card&#237;aco pedi&#225;trico. </p>
    <p><bold>M&#201;TODOS:</bold>Foram coletadas 50 amostras de BNP de 33 crian&#231;as em p&#243;s-operat&#243;rio de transplante card&#237;aco e analisados dados de idade, sexo, cor, grupo sang&#252;&#237;neo, painel imunol&#243;gico, tempo de evolu&#231;&#227;o ap&#243;s o transplante, classe funcional, imunossupress&#227;o utilizada e n&#250;mero de rejei&#231;&#245;es. </p>
    <p> RESULTADOS:Foram 33 crian&#231;as com idade mediana de 10,13 anos, predom&#237;nio do sexo feminino (54%) e da cor branca (78%). No momento da dosagem de BNP o tempo m&#233;dio de transplante foi 4,25 anos. A bi&#243;psia endomioc&#225;rdica diagnosticou nove rejei&#231;&#245;es em oito pacientes (27%), sendo tr&#234;s com grau 3 A, cinco com grau 2 e um com rejei&#231;&#227;o humoral. No momento da bi&#243;psia, a maioria dos pacientes encontrava-se assintom&#225;tica. O n&#237;vel s&#233;rico de BNP foi em m&#233;dia 77,18 pg/ml, sendo 144,22 pg/ml no grupo com rejei&#231;&#227;o e 62,46 pg/ml no grupo sem rejei&#231;&#227;o, com p = 0,02. </p>
    <p> CONCLUS&#195;O: Crian&#231;as assintom&#225;ticas podem apresentar rejei&#231;&#227;o aguda no p&#243;s-operat&#243;rio de transplante card&#237;aco. O n&#237;vel s&#233;rico de BNP apresentou diferen&#231;a estatisticamente significante no grupo com rejei&#231;&#227;o, podendo ser m&#233;todo adicional no diagn&#243;stico de rejei&#231;&#227;o card&#237;aca.</p>
    <p><bold>Palavras-chave: </bold>Transplante de cora&#231;&#227;o, rejei&#231;&#227;o do enxerto, pept&#237;deo natriur&#233;tico tipo B, bi&#243;psia, crian&#231;as.</p>
    <p>
      <bold>Introdu&#231;&#227;o</bold>
    </p>
    <p>Apesar dos recentes avan&#231;os descritos na terap&#234;utica da insufici&#234;ncia card&#237;aca congestiva em crian&#231;as, o transplante card&#237;aco ainda tem sido op&#231;&#227;o terap&#234;utica em grande n&#250;mero de crian&#231;as portadoras de cardiopatias cong&#234;nitas complexas e cardiomiopatias refrat&#225;rias &#224; terap&#234;utica convencional<sup>1,2</sup>.</p>
    <p>O d&#233;cimo registro da Sociedade Internacional de Transplante Card&#237;aco Pedi&#225;trico (2007)<sup>3</sup> refere que a rejei&#231;&#227;o ainda &#233; uma importante causa de mortalidade p&#243;s-transplante card&#237;aco pedi&#225;trico, apesar dos novos agentes imunossupressores e do desenvolvimento de novas estrat&#233;gias no seu tratamento.</p>
    <p>O diagn&#243;stico precoce &#233; essencial e m&#233;todos n&#227;o-invasivos<sup>4-6</sup> t&#234;m sido investigados em crian&#231;as, pois a bi&#243;psia endomioc&#225;rdica, apesar de ser considerada m&#233;todo de escolha, apresenta limita&#231;&#245;es pelas dificuldades t&#233;cnicas, custos e complica&#231;&#245;es quando realizada em crian&#231;as<sup>7-9</sup>.</p>
    <p>O n&#237;vel s&#233;rico do pept&#237;deo natriur&#233;tico tipo B (BNP), neuro-horm&#244;nio produzido pelo mioc&#225;rdio em resposta &#224; distens&#227;o do ventr&#237;culo ou aumento da tens&#227;o da parede<sup>10-12</sup>, tem sido utilizado no transplante card&#237;aco, em pacientes adultos, como m&#233;todo diagn&#243;stico de rejei&#231;&#227;o aguda<sup>13</sup>, e como preditor de coronariopatia<sup>14-16</sup>. Na popula&#231;&#227;o pedi&#225;trica s&#227;o poucos relatos, com pequeno n&#250;mero de pacientes e resultados controversos, o que nos motivou &#224; realiza&#231;&#227;o deste estudo<sup>17,18</sup>.</p>
    <p>A pesquisa consiste na avalia&#231;&#227;o do n&#237;vel s&#233;rico de BNP em compara&#231;&#227;o aos achados histopatol&#243;gicos da bi&#243;psia endomioc&#225;rdica, visando ao diagn&#243;stico de rejei&#231;&#227;o aguda em crian&#231;as submetidas ao transplante card&#237;aco ortot&#243;pico.</p>
    <p>
      <bold>M&#233;todos</bold>
    </p>
    <p>Realizou-se estudo transversal em 33 pacientes na faixa et&#225;ria pedi&#225;trica, em seguimento ap&#243;s transplante card&#237;aco no Instituto do Cora&#231;&#227;o do Hospital das Cl&#237;nicas da Faculdade de Medicina da Universidade de S&#227;o Paulo, durante o per&#237;odo compreendido entre junho de 2005 e outubro de 2006, totalizando 50 bi&#243;psias.</p>
    <p>Os crit&#233;rios de inclus&#227;o utilizados para a realiza&#231;&#227;o do estudo foram: pacientes com mais de seis meses de evolu&#231;&#227;o ap&#243;s o transplante card&#237;aco, cujos respons&#225;veis concordaram com a realiza&#231;&#227;o do cateterismo card&#237;aco e do protocolo do estudo, assinando um termo de consentimento.</p>
    <p>Foram exclu&#237;dos: pacientes que n&#227;o realizaram cateterismo card&#237;aco no per&#237;odo do estudo e casos com falha na coleta ou armazenamento do material.</p>
    <p>Os par&#226;metros cl&#237;nicos avaliados foram: altera&#231;&#227;o de humor (irritabilidade, apatia, agita&#231;&#227;o, sonol&#234;ncia) ou presen&#231;a de anorexia, febre, arritmia ou sinais de insufici&#234;ncia card&#237;aca congestiva.</p>
    <p>Foram coletados dados evolutivos como tempo de evolu&#231;&#227;o ap&#243;s transplante, n&#250;mero total de epis&#243;dios de rejei&#231;&#227;o, idade no momento do transplante e imunossupress&#227;o utilizada, al&#233;m de necessidade de agentes vasoativos e/ou medica&#231;&#227;o anticongestiva, assim como presen&#231;a de coronariopatia, insufici&#234;ncia renal ou diabete melito.</p>
    <p>
      <bold>Coleta do BNP</bold>
    </p>
    <p>O BNP foi coletado no momento da bi&#243;psia endomioc&#225;rdica das crian&#231;as submetidas a transplante card&#237;aco. O m&#233;todo de dosagem de BNP utilizado foi o teste Triage<sup>R</sup> (Biosite Diagnostics), teste de imunofluoresc&#234;ncia para determina&#231;&#227;o quantitativa do BNP em sangue ou plasma conservados com EDTA como anticoagulante. Depois de colocada a amostra de sangue no dispositivo, o sangue &#233; separado do plasma por um filtro. Uma quantidade predeterminada de plasma &#233; colocada sob rea&#231;&#227;o com anticorpos fluorescentes. Depois de um per&#237;odo de incuba&#231;&#227;o, a amostra segue para uma an&#225;lise que detecta os complexos formados com os anticorpos fluorescentes.</p>
    <p>Neste estudo foi utilizado material com per&#237;odo m&#225;ximo de seis meses de coleta, congelado a menos 20&#186; Celsius.</p>
    <p>
      <bold>Bi&#243;psia endomioc&#225;rdica</bold>
    </p>
    <p>As bi&#243;psias foram feitas de forma consecutiva, e indicadas nos casos com suspeita de rejei&#231;&#227;o aguda e durante a realiza&#231;&#227;o do cateterismo anual.</p>
    <p>Para an&#225;lise dos dados os pacientes foram divididos em grupo com rejei&#231;&#227;o e sem rejei&#231;&#227;o, sendo avaliados os n&#237;veis de BNP nos dois grupos. Foi considerada rejei&#231;&#227;o aguda celular quando a bi&#243;psia endomioc&#225;rdica mostrou achados compat&#237;veis com rejei&#231;&#227;o celular grau igual ou maior que 2 ou presen&#231;a de rejei&#231;&#227;o humoral, de acordo com os crit&#233;rios da Sociedade Internacional de Transplante Card&#237;aco e Pulmonar (ISHLT)<sup>19</sup>.</p>
    <p>
      <bold>Ecocardiograma</bold>
    </p>
    <p>O ecocardiograma foi realizado segundo as recomenda&#231;&#245;es da Sociedade Americana de Ecocardiografia<sup>20</sup> visando analisar os seguintes par&#226;metros: di&#226;metro de septo e parede na di&#225;stole, di&#226;metro sist&#243;lico e diast&#243;lico do ventr&#237;culo esquerdo, grau de insufici&#234;ncia valvar, presen&#231;a de derrame peric&#225;rdico e sinais de disfun&#231;&#227;o diast&#243;lica (com observa&#231;&#227;o do fluxo transmitral e an&#225;lise do Doppler tecidual no n&#237;vel do anel mitral). A fra&#231;&#227;o de eje&#231;&#227;o foi calculada por meio do m&#233;todo de Teichholz.</p>
    <p>A fun&#231;&#227;o diast&#243;lica foi avaliada por meio do fluxo transvalvar mitral obtido pelo Doppler pulsado no plano apical quatro c&#226;maras, sendo observado o padr&#227;o de velocidades das ondas mitrais E (fase de enchimento r&#225;pido) e A (contra&#231;&#227;o atrial), e considerado normal a raz&#227;o E/A maior ou igual a 1,0, altera&#231;&#227;o de relaxamento ventricular com raz&#227;o E/A menor que 1,0 e padr&#227;o restritivo com raz&#227;o E/A maior que 1,5.</p>
    <p>O Doppler tecidual, t&#233;cnica que avalia a velocidade de movimenta&#231;&#227;o do mioc&#225;rdio, foi avaliado no n&#237;vel do &#226;nulo mitral lateral no plano apical quatro c&#226;maras, sendo anormal a invers&#227;o do padr&#227;o normal das ondas E' (onda diast&#243;lica precoce) e A' (onda diast&#243;lica tardia) com E'&lt;A' ou redu&#231;&#227;o da velocidade da onda E'. Quando observada alguma altera&#231;&#227;o na morfologia ou na amplitude das ondas, realizou-se estudo nas demais paredes do ventr&#237;culo esquerdo e ventr&#237;culo direito.</p>
    <p>
      <bold>An&#225;lise estat&#237;stica</bold>
    </p>
    <p>Foi realizada an&#225;lise descritiva dos dados dos 33 pacientes, quanto &#224;s informa&#231;&#245;es referentes aos dados demogr&#225;ficos, cl&#237;nicos, de exames pr&#233; e p&#243;s-transplante.</p>
    <p>As vari&#225;veis quantitativas foram resumidas pelas medidas de tend&#234;ncia central e de dispers&#227;o (valores m&#237;nimo, m&#225;ximo, mediana, m&#233;dia e desvio padr&#227;o). Os dados qualitativos foram analisados por tabelas de freq&#252;&#234;ncias absolutas e relativas. Foram elaborados gr&#225;ficos com a finalidade de ilustrar os dados.</p>
    <p>Para avalia&#231;&#227;o das diferen&#231;as entre as concentra&#231;&#245;es de BNP nos grupos com ou sem rejei&#231;&#227;o utilizou-se o teste Mann-Whitney (n&#227;o-param&#233;trico). Al&#233;m disso, foram calculadas a sensibilidade e a especificidade por meio da curva ROC para estabelecer como cut-off o valor de maior sensibilidade na detec&#231;&#227;o dos pacientes com rejei&#231;&#227;o aguda, adotando-se como padr&#227;o de refer&#234;ncia o resultado da bi&#243;psia.</p>
    <p>Para avaliar comparativamente o ecocardiograma e a dosagem de BNP (exames n&#227;o-invasivos) com o padr&#227;o de refer&#234;ncia (a bi&#243;psia endomioc&#225;rdica) no diagn&#243;stico de rejei&#231;&#227;o aguda foram calculados &#237;ndices de sensibilidade e especificidade, valor preditivo positivo e valor preditivo negativo.</p>
    <p>Os resultados foram interpretados utilizando-se o n&#237;vel de signific&#226;ncia (&#945;) de 5%<sup>21,22</sup>.</p>
    <p>
      <bold>Procedimentos &#233;ticos para realiza&#231;&#227;o da pesquisa</bold>
    </p>
    <p>O trabalho foi realizado de acordo com os crit&#233;rios de seguimento para os pacientes transplantados no Instituto do Cora&#231;&#227;o (InCor) do Hospital das Cl&#237;nicas da FMUSP e n&#227;o acarretou nenhum risco suplementar aos envolvidos no estudo. O exame do BNP, como m&#233;todo de diagn&#243;stico e experimento, n&#227;o apresentou contra-indica&#231;&#245;es, preparo especial do paciente ou efeitos colaterais. As medidas de coleta do material e de prote&#231;&#227;o aos pacientes foram aquelas j&#225; empregadas na institui&#231;&#227;o para pacientes imunossuprimidos de acordo com as normas da comiss&#227;o de controle de infec&#231;&#227;o hospitalar.</p>
    <p>
      <bold>Resultados</bold>
    </p>
    <p>Foram 33 crian&#231;as estudadas com idade m&#233;dia de 11 anos (4 a 19 anos), com mediana de 10,13 anos e desvio padr&#227;o de 4,55 anos; predom&#237;nio do sexo feminino (54,5%) e da ra&#231;a branca (84,8%). Dados antropom&#233;tricos: peso de 12 a 78 kg, com mediana de 29,0 kg; estatura de 90 a 170 cm com mediana de 136,0 cm e &#237;ndice de massa corp&#243;rea (IMC) com mediana de 16,35 e desvio padr&#227;o de 3,78.</p>
    <p>A indica&#231;&#227;o de transplante card&#237;aco se deu por cardiomiopatia dilatada em 22 (67%) pacientes, cardiomiopatia restritiva em dois (6%), cardiopatia cong&#234;nita em oito (24%) e cardiopatia reum&#225;tica em um paciente (3%).</p>
    <p>Quanto &#224; distribui&#231;&#227;o dos pacientes segundo o grupo sang&#252;&#237;neo, 15 (45,0%) eram do Grupo O; 12 (36,0%) eram do grupo A; tr&#234;s (9,0%), do grupo B; e tr&#234;s (9,0%). do grupo AB.</p>
    <p>O tempo de evolu&#231;&#227;o ap&#243;s o transplante no momento da dosagem de BNP apresentou mediana de 4,25 anos (seis meses a 13,6 anos). A idade m&#233;dia no momento do transplante foi de 4,90 anos (quatro meses a 15 anos).</p>
    <p>Em rela&#231;&#227;o &#224; imunossupress&#227;o, inibidor de calcineurina e micofenolato mofetil foram os agentes mais utilizados (78,7% e 66,6%, respectivamente), sendo menor a propor&#231;&#227;o de pacientes em uso cr&#244;nico de inibidor de calcineurina e azatioprina e cortic&#243;ide. O n&#250;mero de rejei&#231;&#245;es foi em m&#233;dia de 3, mais ou menos 1,4 rejei&#231;&#227;o por paciente.</p>
    <p>A bi&#243;psia endomioc&#225;rdica diagnosticou rejei&#231;&#227;o em nove pacientes (27%), sendo tr&#234;s com grau 3 A, cinco com grau 2 e uma rejei&#231;&#227;o humoral sem sinais de rejei&#231;&#227;o celular (<xref ref-type="fig" rid="g1">gr&#225;fico 1</xref>).</p>
    <fig id="g1">
      <graphic xlink:href="1678-4170-abc-92-03-0227-00011-gf01.jpg"/></fig>
    <p>Em rela&#231;&#227;o &#224; sintomatologia, a maioria dos pacientes encontrava-se assintom&#225;tica no momento do exame, sendo realizado o cateterismo durante procedimento de rotina em 36 amostras (72%). A suspeita cl&#237;nica de rejei&#231;&#227;o (altera&#231;&#227;o de humor, presen&#231;a de arritmia ou altera&#231;&#227;o ao ecocardiograma) ocorreu em 10 pacientes (20%), e quatro amostras (8%) foram coletadas como controle ap&#243;s tratamento de rejei&#231;&#227;o.</p>
    <p>O n&#237;vel s&#233;rico de BNP foi em m&#233;dia 79,9 pg/ml, sendo de 144,2 pg/ml no grupo com rejei&#231;&#227;o e de 65,80 no grupo sem rejei&#231;&#227;o, com p = 0,02 (<xref ref-type="fig" rid="g2">Gr&#225;fico 2</xref>). An&#225;lise por curva ROC encontrou-se o valor de 38 pg/ml como o valor de sensibilidade 100% e especificidade 56% para diagn&#243;stico de rejei&#231;&#227;o card&#237;aca, com &#225;rea sobre a curva de 0,74 e p 0,01 (<xref ref-type="fig" rid="g3">Gr&#225;fico 3</xref>).</p>
    <fig id="g2">
      <graphic xlink:href="1678-4170-abc-92-03-0227-00011-gf02.jpg"/></fig>
    <fig id="g3">
      <graphic xlink:href="1678-4170-abc-92-03-0227-00011-gf03.jpg"/></fig>
    <p>
      <bold>Ecocardiograma</bold>
    </p>
    <p>A an&#225;lise ecocardiogr&#225;fica (<xref ref-type="table" rid="t1">tab.1</xref>) encontrou altera&#231;&#245;es em 4 das 9 amostras com rejei&#231;&#227;o (44%) e em 4 das 41 bi&#243;psias sem rejei&#231;&#227;o (10%), com valor preditivo positivo de 50% e valor preditivo negativo de 88%, A sensibilidade do m&#233;todo foi de 44% e especificidade de 90% (p 0,02).</p>
    <table-wrap id="t1">
      <graphic xlink:href="1678-4170-abc-92-03-0227-00011-gt01.jpg"/></table-wrap>
    <p>As altera&#231;&#245;es encontradas nos pacientes com rejei&#231;&#227;o foram: disfun&#231;&#227;o sist&#243;lica moderada biventricular em paciente com rejei&#231;&#227;o humoral, disfun&#231;&#227;o sist&#243;lica discreta de ventr&#237;culo esquerdo em paciente com rejei&#231;&#227;o grau 2 e em dois pacientes com grau 3 A foram observadas, respectivamente, insufici&#234;ncia mitral moderada e altera&#231;&#227;o de fun&#231;&#227;o diast&#243;lica tipo altera&#231;&#227;o de relaxamento, com invers&#227;o do padr&#227;o das ondas E' e A' ao Doppler tecidual.</p>
    <p>
      <bold>Hemodin&#226;mica</bold>
    </p>
    <p>Comparados os grupos com e sem rejei&#231;&#227;o (<xref ref-type="table" rid="t2">tab.2</xref>), n&#227;o se observou diferen&#231;a em rela&#231;&#227;o a press&#227;o sist&#243;lica pulmonar, press&#227;o capilar pulmonar, d&#233;bito card&#237;aco, resist&#234;ncia vascular pulmonar ou sist&#234;mica.</p>
    <table-wrap id="t2">
      <graphic xlink:href="1678-4170-abc-92-03-0227-00011-gt02.jpg"/></table-wrap>
    <p>Em rela&#231;&#227;o &#224; presen&#231;a ou n&#227;o de coronariopatia e altera&#231;&#245;es do BNP, observaram-se n&#237;veis maiores que 100 pg/ml em tr&#234;s dos quatro pacientes com coronariopatia (p=0,01).</p>
    <p>
      <bold>BNP e insufici&#234;ncia renal</bold>
    </p>
    <p>Observou-se eleva&#231;&#227;o dos n&#237;veis de BNP n&#227;o relacionado &#224; rejei&#231;&#227;o em dois pacientes com altera&#231;&#227;o de fun&#231;&#227;o renal, BNP= 208 pg/ml e 291 pg/ml, (p=0,02).</p>
    <p>
      <bold>Discuss&#227;o</bold>
    </p>
    <p>Diante de quadros de rejei&#231;&#227;o importante em pacientes assintom&#225;ticos com possibilidade de morte s&#250;bita, a procura por m&#233;todos n&#227;o-invasivos, com alta sensibilidade e especificidade, que possam ser repetidos de forma r&#225;pida e em curto per&#237;odo de tempo, tem ocupado grande parte da literatura mundial em transplante card&#237;aco.</p>
    <p>Estudos mostram o BNP e o NT- proBNP como marcadores fidedignos em transplante e insufici&#234;ncia card&#237;aca, orientando terap&#234;utica e colaborando no diagn&#243;stico e no progn&#243;stico<sup>23,24</sup>.</p>
    <p>Avalia&#231;&#227;o da express&#227;o g&#234;nica de pacientes p&#243;s-transplante em fase cr&#244;nica, sem altera&#231;&#245;es hemodin&#226;micas e livres de rejei&#231;&#227;o, correlaciona o aumento s&#233;rico de BNP com genes presentes em processos inflamat&#243;rios iniciais, remodelamento card&#237;aco, ativa&#231;&#227;o imune e altera&#231;&#245;es vasculares<sup>25</sup>, sendo assim pass&#237;vel predizer de forma precoce o desenvolvimento de coronariopatia ou rejei&#231;&#227;o.</p>
    <p>Lan e cols.<sup>26</sup>, estudando crian&#231;as em p&#243;s-operat&#243;rio de transplante card&#237;aco, observaram n&#237;veis elevados de BNP no primeiro m&#234;s ap&#243;s o transplante, com decline gradual ap&#243;s esse per&#237;odo, e normaliza&#231;&#227;o dos valores (&lt; 100 pg/ml) em 14 semanas.</p>
    <p>A rejei&#231;&#227;o aguda, como demonstrado em nosso estudo, pode ocorrer em crian&#231;as de maneira assintom&#225;tica no p&#243;s-operat&#243;rio de transplante card&#237;aco, e a avalia&#231;&#227;o dos n&#237;veis s&#233;ricos de BNP pode ser um indicador precoce dessa rejei&#231;&#227;o, especialmente nas formas mais graves como a rejei&#231;&#227;o humoral<sup>27-31</sup>.</p>
    <p>A praticidade na realiza&#231;&#227;o do exame, podendo ser feito no consult&#243;rio com resultado imediato, possibilita a repeti&#231;&#227;o em casos com suspeita cl&#237;nica de rejei&#231;&#227;o ou mesmo nas consultas ambulatoriais de rotina, permitindo com isso postergar a realiza&#231;&#227;o do cateterismo card&#237;aco, reduzindo as taxas de morbidade dessas crian&#231;as.</p>
    <p>O valor encontrado neste estudo como corte para diagn&#243;stico de rejei&#231;&#227;o card&#237;aca aguda avaliado por meio de curva ROC, com sensibilidade de 100%, foi de 38 pg/ml, podendo ser esse dado um indicativo de que podemos levar em conta valores menores, priorizando a sensibilidade do m&#233;todo.</p>
    <p>O ecocardiograma, apesar da baixa sensibilidade para o diagn&#243;stico de rejei&#231;&#227;o card&#237;aca, &#233; um exame de f&#225;cil execu&#231;&#227;o e de alta especificidade, achados consistentes com os relatados por Akioka e cols.<sup>32</sup>, devendo ser utilizado de forma comparativa e dispondo de todos os recursos atuais dispon&#237;veis, incluindo a an&#225;lise por meio do Doppler tecidual. Mais estudos s&#227;o necess&#225;rios visando aumentar a sensibilidade do m&#233;todo.</p>
    <p>A avalia&#231;&#227;o de medidas hemodin&#226;micas, exceto pela redu&#231;&#227;o do d&#233;bito card&#237;aco, n&#227;o apresentou neste estudo correla&#231;&#227;o com os resultados de bi&#243;psia, dados concordantes com descri&#231;&#245;es da literatura<sup>33-35</sup>. A correla&#231;&#227;o entre aumento de BNP e presen&#231;a de coronariopatia foi significativa nessa amostra, mostrando a import&#226;ncia do m&#233;todo tamb&#233;m como triagem de doen&#231;a vascular do enxerto.</p>
    <p>
      <bold>Limita&#231;&#245;es do estudo</bold>
    </p>
    <p>O n&#250;mero limitado de pacientes, e conseq&#252;entemente o pequeno grupo com rejei&#231;&#227;o, dificultou a an&#225;lise de subgrupos.</p>
    <p>
      <bold>Implica&#231;&#245;es cl&#237;nicas</bold>
    </p>
    <p>O BNP demonstrou ser um exame auxiliar importante no diagn&#243;stico de rejei&#231;&#227;o card&#237;aca, especialmente nos casos mais graves, como rejei&#231;&#227;o humoral.</p>
    <p>Trata-se de exame de f&#225;cil execu&#231;&#227;o, pouco invasivo e de resultado imediato, podendo ser repetido de forma seriada visando postergar a realiza&#231;&#227;o da bi&#243;psia endomioc&#225;rdica.</p>
    <p>A correla&#231;&#227;o com coronariopatia tamb&#233;m ressalta a import&#226;ncia do m&#233;todo no seguimento de longo prazo das crian&#231;as em p&#243;s-operat&#243;rio tardio de transplante card&#237;aco, considerando que essa &#233; uma importante causa de mortalidade ap&#243;s cinco anos de transplante, e muitas vezes se manifestando com morte s&#250;bita em pacientes ambulatoriais.</p>
    <p>
      <bold>Conclus&#227;o</bold>
    </p>
    <p>A rejei&#231;&#227;o aguda pode ocorrer de forma assintom&#225;tica em crian&#231;as no p&#243;s-operat&#243;rio tardio de transplante card&#237;aco e a dosagem do n&#237;vel s&#233;rico de BNP, realizada de forma seriada, pode auxiliar no diagn&#243;stico dessa rejei&#231;&#227;o.</p>
    <p>
      <bold>Potencial Conflito de Interesses</bold>
    </p>
    <p>Declaro n&#227;o haver conflito de interesses pertinentes.</p>
    <p>
      <bold>Fontes de Financiamento</bold>
    </p>
    <p>O presente estudo foi parcialmente financiado por FAPESP.</p>
    <p>
      <bold>Vincula&#231;&#227;o Acad&#234;mica</bold>
    </p>
    <p>Este artigo &#233; parte de tese de Doutorado de Cristina de Sylos, pela Faculdade de Medicina da Universidade de S&#227;o Paulo.</p>
    <p>
      <fn id="back" fn-type="corresp">
        <p>Correspond&#234;ncia:</p>
        <p> Cristina de Sylos </p>
        <p> Rua Fernando Pessoa, 53 (Vila Giglio) </p>
        <p> 12946-240 - Atibaia, SP - Brasil </p>
        <p> E-mail: </p>
        <p>
          <email xlink:href="cristinasylos@hotmail.com">cristinasylos@hotmail.com</email>
        </p>
      </fn>
    </p>
    <p>Artigo recebido em 11/04/08; revisado recebido em 04/07/08; aceito em 31/07/08.</p>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <mixed-citation>1. Azeka E, Barbero-Marcial    M, Jatene M, Auler JO, Ramires JA. Eight years experience of pediatric heart    transplantation: clinical outcome using non-invasive methods for the evaluation    of acute rejection. Pediatr Transplant. 2002; 6 (3): 208-13.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Eight years experience of pediatric heart transplantation: clinical outcome using non-invasive methods for the evaluation of acute rejection</article-title>
          <source>Pediatr Transplant</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>208</fpage>
          <lpage>13</lpage>
          <issue>3</issue>
          <volume>6</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Azeka</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Barbero-Marcial</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Jatene</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Auler</surname>
              <given-names>JO</given-names>
            </name>
            <name>
              <surname>Ramires</surname>
              <given-names>JA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B2">
        <mixed-citation>2. Azeka E, Ramires    JA, Valler C, Bocchi E. Delisting of infants and children from the heart transplantation    waiting list after carvedilol treatment. J Am Coll Cardiol. 2002; 40 (11): 2034-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Delisting of infants and children from the heart transplantation waiting list after carvedilol treatment</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>2034</fpage>
          <lpage>8</lpage>
          <issue>11</issue>
          <volume>40</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Azeka</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Ramires</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Valler</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Bocchi</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B3">
        <mixed-citation>3. Boucek MM, Aurora    P, Edwards LB, Taylor DO, Trulock EP, Christie J, et al. Registry of the International    Society for Heart and Lung Transplantation: tenth official pediatric heart transplantation    report - 2007. J Heart Lung Transplant. 2007; 26 (8): 796-807.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Registry of the International Society for Heart and Lung Transplantation: tenth official pediatric heart transplantation report - 2007</article-title>
          <source>J Heart Lung Transplant</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>796</fpage>
          <lpage>807</lpage>
          <issue>8</issue>
          <volume>26</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Boucek</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Aurora</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Edwards</surname>
              <given-names>LB</given-names>
            </name>
            <name>
              <surname>Taylor</surname>
              <given-names>DO</given-names>
            </name>
            <name>
              <surname>Trulock</surname>
              <given-names>EP</given-names>
            </name>
            <name>
              <surname>Christie</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B4">
        <mixed-citation>4. Azeka E, Barbero    Marcial M, Soares J, Camargo PR, Jatene M, Auler JO, et al. The importance of    noninvasive methods on the evaluation of acute rejection in pediatric transplantation:    Gallium 67 scintigraphy as an option. In: 2nd World Congress Pediatric Cardiology    and Cardiac Surgery, Honolulu, 1998. Proceedings. Honolulu; 1998. p. 133-6.</mixed-citation>
        <element-citation publication-type="confproc">
          <source>Proceedings</source>
          <date>
            <year>1998</year>
          </date>
          <fpage>133</fpage>
          <lpage>6</lpage>
          <person-group person-group-type="author">
            <name>
              <surname>Azeka</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Barbero Marcial</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Soares</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Camargo</surname>
              <given-names>PR</given-names>
            </name>
            <name>
              <surname>Jatene</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Auler</surname>
              <given-names>JO</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B5">
        <mixed-citation>5. Azeka E. Transplante    card&#237;aco em crian&#231;as - an&#225;lise cl&#237;nica evolutiva.    [Tese]. S&#227;o Paulo: Faculdade de Medicina da Universidade de S&#227;o    Paulo; 1998.</mixed-citation>
        <element-citation publication-type="thesis">
          <source>Transplante card&#237;aco em crian&#231;as - an&#225;lise cl&#237;nica evolutiva</source>
          <date>
            <year>1998</year>
          </date>
          <person-group person-group-type="author">
            <name>
              <surname>Azeka</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B6">
        <mixed-citation>6. Zales VR, Crawford    S, Backer CL, Pahl E, Webb CL, Lynch P, et al. Role of endomyocardial biopsy    in rejection surveillance after heart transplantation in neonates and children.    J Am Coll Cardiol. 1999; 23 (3): 766-71.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Role of endomyocardial biopsy in rejection surveillance after heart transplantation in neonates and children</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>766</fpage>
          <lpage>71</lpage>
          <issue>3</issue>
          <volume>23</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Zales</surname>
              <given-names>VR</given-names>
            </name>
            <name>
              <surname>Crawford</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Backer</surname>
              <given-names>CL</given-names>
            </name>
            <name>
              <surname>Pahl</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Webb</surname>
              <given-names>CL</given-names>
            </name>
            <name>
              <surname>Lynch</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B7">
        <mixed-citation>7. Wagner K, Oliver    MC, Boyle GJ, Miller SA, Law YM, Pigula F, et al. Endomyocardial biopsy in pediatric    heart transplant recipients; a useful exercise? (Analysis of 1169 biopsies).    Pediatr Transplant. 2000; 4 (3): 186-92.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Endomyocardial biopsy in pediatric heart transplant recipients; a useful exercise? (Analysis of 1169 biopsies)</article-title>
          <source>Pediatr Transplant</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>186</fpage>
          <lpage>92</lpage>
          <issue>3</issue>
          <volume>4</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Wagner</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Oliver</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Boyle</surname>
              <given-names>GJ</given-names>
            </name>
            <name>
              <surname>Miller</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Law</surname>
              <given-names>YM</given-names>
            </name>
            <name>
              <surname>Pigula</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B8">
        <mixed-citation>8. Siaplaouras    J, Thul J, Kramer U, Bauer J, Schranz D. Cardiac troponin I: a marker of acute    heart rejection in infant and child heart recipients. Pediatr Transplant. 2003;    7 (1): 43-5.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Cardiac troponin I: a marker of acute heart rejection in infant and child heart recipients</article-title>
          <source>Pediatr Transplant</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>43</fpage>
          <lpage>5</lpage>
          <issue>1</issue>
          <volume>7</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Siaplaouras</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Thul</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Kramer</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Bauer</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Schranz</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B9">
        <mixed-citation>9. Arnau-Vives    MA, Almenar L, Hervas I, Osa A, Martinez-Dolz L, Rueda J, et al. Preditive value    of brain natriuretic peptide in the diagnosis of heart transplant rejection.    J Heart Lung Transplant. 2004; 23 (7): 850-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Preditive value of brain natriuretic peptide in the diagnosis of heart transplant rejection</article-title>
          <source>J Heart Lung Transplant</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>850</fpage>
          <lpage>6</lpage>
          <issue>7</issue>
          <volume>23</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Arnau-Vives</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Almenar</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Hervas</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Osa</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Martinez-Dolz</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Rueda</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B10">
        <mixed-citation>10. Park MH, Uber    PA, Scott RL, Mehra MR. B-type natriuretic peptide in heart transplantation:    an important marker of allograft performance. Heart Fail Rev. 2003, 8 (4): 359-63.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>B-type natriuretic peptide in heart transplantation: an important marker of allograft performance</article-title>
          <source>Heart Fail Rev</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>359</fpage>
          <lpage>63</lpage>
          <issue>4</issue>
          <volume>8</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Park</surname>
              <given-names>MH</given-names>
            </name>
            <name>
              <surname>Uber</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Scott</surname>
              <given-names>RL</given-names>
            </name>
            <name>
              <surname>Mehra</surname>
              <given-names>MR</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B11">
        <mixed-citation>11. Abramson LP,    Pahl E, Huang L, Stellmach V, Rodgers S, Mavroudis C, et al. Serum vascular    endothelial growth factor as a surveillance marker for cellular rejection in    pediatric cardiac transplantation. Transplantation. 2002; 73 (1): 153-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Serum vascular endothelial growth factor as a surveillance marker for cellular rejection in pediatric cardiac transplantation</article-title>
          <source>Transplantation</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>153</fpage>
          <lpage>6</lpage>
          <issue>1</issue>
          <volume>73</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Abramson</surname>
              <given-names>LP</given-names>
            </name>
            <name>
              <surname>Pahl</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Stellmach</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Rodgers</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Mavroudis</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B12">
        <mixed-citation>12. Troughton RW,    Prior DL, Pereira JJ, Martin M, Fogarty A, Morehead A, et al. Plasma brain natriuretic    peptide levels in systolic heart failure: importance of left ventricular diastolic    function and right ventricular systolic function. J Am Coll Cardiol. 2004; 43    (3): 416-22.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Plasma brain natriuretic peptide levels in systolic heart failure: importance of left ventricular diastolic function and right ventricular systolic function</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>416</fpage>
          <lpage>22</lpage>
          <issue>3</issue>
          <volume>43</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Troughton</surname>
              <given-names>RW</given-names>
            </name>
            <name>
              <surname>Prior</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>Pereira</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Martin</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Fogarty</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Morehead</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B13">
        <mixed-citation>13. Bibbins-Domingo    K, Ansari M, Schiller NB, Massie B, Whooley MA. B-natriuretic peptide and ischemia    in patients with stable coronary disease. Circulation. 2003; 108 (24): 2987-92.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>B-natriuretic peptide and ischemia in patients with stable coronary disease</article-title>
          <source>Circulation</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>2987</fpage>
          <lpage>92</lpage>
          <issue>24</issue>
          <volume>108</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Bibbins-Domingo</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Ansari</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Schiller</surname>
              <given-names>NB</given-names>
            </name>
            <name>
              <surname>Massie</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Whooley</surname>
              <given-names>MA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B14">
        <mixed-citation>14. Mayer SA, De    Lemos JA, Murphy SA, Brooks S, Robert BJ, Grayburn PA. Comparison of B-natriuretic    peptide levels in patients with heart failure versus without mitral regurgitation.    Am J Cardiol. 2004; 15 (8): 1002-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Comparison of B-natriuretic peptide levels in patients with heart failure versus without mitral regurgitation</article-title>
          <source>Am J Cardiol</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>1002</fpage>
          <lpage>6</lpage>
          <issue>8</issue>
          <volume>15</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Mayer</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>De Lemos</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Murphy</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Brooks</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Robert</surname>
              <given-names>BJ</given-names>
            </name>
            <name>
              <surname>Grayburn</surname>
              <given-names>PA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B15">
        <mixed-citation>15. Kruger S, Graf    J, Kumz D, Stickel T, Hanrath P, Jansens U. Brain natriuretic peptide levels    predict functional capacity in patients with chronic heart failure. J Am Coll    Cardiol. 2002; 21 (4): 718-22.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Brain natriuretic peptide levels predict functional capacity in patients with chronic heart failure</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>718</fpage>
          <lpage>22</lpage>
          <issue>4</issue>
          <volume>21</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Kruger</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Graf</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Kumz</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Stickel</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Hanrath</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Jansens</surname>
              <given-names>U</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B16">
        <mixed-citation>16. Tang WH, Girod    JP, Lee MJ, Starling RC, Ypung JB, Van Lente F, et al. Plasma brain natriuretic    peptide levels in ambulatory patients with established chronic symptomatic systolic    heart failure. Circulation. 2003; 208 (24): 2964-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Plasma brain natriuretic peptide levels in ambulatory patients with established chronic symptomatic systolic heart failure</article-title>
          <source>Circulation</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>2964</fpage>
          <lpage>6</lpage>
          <issue>24</issue>
          <volume>208</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Tang</surname>
              <given-names>WH</given-names>
            </name>
            <name>
              <surname>Girod</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Starling</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>Ypung</surname>
              <given-names>JB</given-names>
            </name>
            <name>
              <surname>Van Lente</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B17">
        <mixed-citation>17. Wang TJ, Larson    MG, Levy D, Benjamin E, Leip EP, Omland T, et al. Plasma natriuretic peptide    levels and the risk of cardiovascular events and death. N Engl J Med. 2004;    350 (7): 655-63.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Plasma natriuretic peptide levels and the risk of cardiovascular events and death</article-title>
          <source>N Engl J Med</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>655</fpage>
          <lpage>63</lpage>
          <issue>7</issue>
          <volume>350</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>TJ</given-names>
            </name>
            <name>
              <surname>Larson</surname>
              <given-names>MG</given-names>
            </name>
            <name>
              <surname>Levy</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Benjamin</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Leip</surname>
              <given-names>EP</given-names>
            </name>
            <name>
              <surname>Omland</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B18">
        <mixed-citation>18. Groenning B,    Raymond I, Hildebrandt PR, Nilsson JC, Baumann M, Pedersen F. Diagnostic and    prognostic evaluation of left ventricular systolic heart failure by Plasma N    terminal pro-Brain natriuretic peptide concentration in a large sample of general    population. Heart. 2004; 90 (3): 297-303.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Diagnostic and prognostic evaluation of left ventricular systolic heart failure by Plasma N terminal pro-Brain natriuretic peptide concentration in a large sample of general population</article-title>
          <source>Heart</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>297</fpage>
          <lpage>303</lpage>
          <issue>3</issue>
          <volume>90</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Groenning</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Raymond</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Hildebrandt</surname>
              <given-names>PR</given-names>
            </name>
            <name>
              <surname>Nilsson</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Baumann</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Pedersen</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B19">
        <mixed-citation>19. Billingham    ME, Cary NR, Hammond ME, Kemnitz J, Marboe C, McCallister HA, et al. A working    formulation for the standardization of nomenclature in the diagnosis of heart    and lung rejection: Heart Rejection Study Group. The International Society for    Heart Transplantation. J Heart Transplant. 1990; 9: 587-93.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. The International Society for Heart Transplantation</article-title>
          <source>J Heart Transplant</source>
          <date>
            <year>1990</year>
          </date>
          <fpage>587</fpage>
          <lpage>93</lpage>
          <volume>9</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Billingham</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Cary</surname>
              <given-names>NR</given-names>
            </name>
            <name>
              <surname>Hammond</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Kemnitz</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Marboe</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>McCallister</surname>
              <given-names>HA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B20">
        <mixed-citation>20. Schiller NB,    Shaw PK, Crawford M, De Maria A, Devereux R, Feigenbaun H. Recommendations for    quantitation of the left ventricle by two-dimensional echocardiography. American    Society of Echocardography Committee on Standars. Subcommittee on quantitation    of two dimensional echocardiograms. J Am Soc Echocardiogr. 1989; 2: 358-67.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardography Committee on Standars. Subcommittee on quantitation of two dimensional echocardiograms</article-title>
          <source>J Am Soc Echocardiogr</source>
          <date>
            <year>1989</year>
          </date>
          <fpage>358</fpage>
          <lpage>67</lpage>
          <volume>2</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Schiller</surname>
              <given-names>NB</given-names>
            </name>
            <name>
              <surname>Shaw</surname>
              <given-names>PK</given-names>
            </name>
            <name>
              <surname>Crawford</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>De Maria</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Devereux</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Feigenbaun</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B21">
        <mixed-citation>21. Bickel PJ,    Doksum KA. Mathematical statistics: basic ideas and select topics. San Francisco:    Holden Day; 1997. p. 153-91.</mixed-citation>
        <element-citation publication-type="book">
          <source>Mathematical statistics: basic ideas and select topics</source>
          <date>
            <year>1997</year>
          </date>
          <person-group person-group-type="author">
            <name>
              <surname>Bickel</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Doksum</surname>
              <given-names>KA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B22">
        <mixed-citation>22. Costa Neto    PLO. Estat&#237;stica. S&#227;o Paulo: Ed Edgard Blucher; 1977. p. 78.</mixed-citation>
        <element-citation publication-type="book">
          <source>Estat&#237;stica</source>
          <date>
            <year>1977</year>
          </date>
          <person-group person-group-type="author">
            <name>
              <surname>Costa Neto</surname>
              <given-names>PLO</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B23">
        <mixed-citation>23. Shou M, Gustafsson    F, Nielsem PH, Madsen LH, Kjaer A, Hildebrandt R. Unexplained week-to-week variation    in BNP and NT-proBNP is low in chronic heart failure during steady state. Eur    J Heart Fail. 2007; 9: 68-74.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Unexplained week-to-week variation in BNP and NT-proBNP is low in chronic heart failure during steady state</article-title>
          <source>Eur J Heart Fail</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>68</fpage>
          <lpage>74</lpage>
          <volume>9</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Shou</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gustafsson</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Nielsem</surname>
              <given-names>PH</given-names>
            </name>
            <name>
              <surname>Madsen</surname>
              <given-names>LH</given-names>
            </name>
            <name>
              <surname>Kjaer</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hildebrandt</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B24">
        <mixed-citation>24. Shaw S, Williams    SG. Is brain natriuretic peptide clinically useful after cardiac transplantation.    J Heart Lung Transplant. 2005; 12: 1396-401.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Is brain natriuretic peptide clinically useful after cardiac transplantation</article-title>
          <source>J Heart Lung Transplant</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>1396</fpage>
          <lpage>401</lpage>
          <volume>12</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Shaw</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Williams</surname>
              <given-names>SG</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B25">
        <mixed-citation>25. Mehra MR, Uber    WE, Walther D, Vesely M, Wohlgemuth JG, Prentice J, et al. Gene expression profiles    and B-type natriuretic peptide elevation in heart transplantation: more than    a hemodynamic marker. Circulation. 2006; 4: 21-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Gene expression profiles and B-type natriuretic peptide elevation in heart transplantation: more than a hemodynamic marker</article-title>
          <source>Circulation</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>21</fpage>
          <lpage>6</lpage>
          <volume>4</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Mehra</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Uber</surname>
              <given-names>WE</given-names>
            </name>
            <name>
              <surname>Walther</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Vesely</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Wohlgemuth</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Prentice</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B26">
        <mixed-citation>26. Lan YT, Chang    RK, Alejos JC, Burch C, Wetzel GT. B-type natriuretic peptide in children after    cardiac transplantation. J Heart Lung Transplant. 2004; 23 (5): 558-63.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>B-type natriuretic peptide in children after cardiac transplantation</article-title>
          <source>J Heart Lung Transplant</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>558</fpage>
          <lpage>63</lpage>
          <issue>5</issue>
          <volume>23</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Lan</surname>
              <given-names>YT</given-names>
            </name>
            <name>
              <surname>Chang</surname>
              <given-names>RK</given-names>
            </name>
            <name>
              <surname>Alejos</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Burch</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Wetzel</surname>
              <given-names>GT</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B27">
        <mixed-citation>27. Hervas I, Almenar    L, Perez-Pastor JL, Chirivella M, Osa A, Martinez-Doltz P, et al. Radioimmunometric    assay of B-type natriuretic peptide (BNP) in heart transplantation: correlation    between BNP determination and biopsy grading of rejection. Nucl Med Commun.    2003; 24 (8): 925-31.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Radioimmunometric assay of B-type natriuretic peptide (BNP) in heart transplantation: correlation between BNP determination and biopsy grading of rejection</article-title>
          <source>Nucl Med Commun</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>925</fpage>
          <lpage>31</lpage>
          <issue>8</issue>
          <volume>24</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Hervas</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Almenar</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Perez-Pastor</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Chirivella</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Osa</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Martinez-Doltz</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B28">
        <mixed-citation>28. Ationu A, Sorensen    K, Whitehead B, Singer D, Burch M, Carter ND. Ventricular expression of brain    natriuretic peptide gene following orthotopic cardiac transplantation in children    - a three year follow up. Cardiovasc Res. 1993; 27 (12): 2135-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Ventricular expression of brain natriuretic peptide gene following orthotopic cardiac transplantation in children - a three year follow up</article-title>
          <source>Cardiovasc Res</source>
          <date>
            <year>1993</year>
          </date>
          <fpage>2135</fpage>
          <lpage>9</lpage>
          <issue>12</issue>
          <volume>27</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Ationu</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Sorensen</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Whitehead</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Singer</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Burch</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Carter</surname>
              <given-names>ND</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B29">
        <mixed-citation>29. Ilene Claudius    MD, Yueh-Tze Lan MD, Chang RK, Wetzel GT, Alejos J. Usefulness of B-type natriuretic    peptide as a noninvasive screening tool for cardiac allograft pathology in pediatric    heart transplant recipients. Am J Cardiol. 2003; 92 (11): 1368-70.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Usefulness of B-type natriuretic peptide as a noninvasive screening tool for cardiac allograft pathology in pediatric heart transplant recipients</article-title>
          <source>Am J Cardiol</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>1368</fpage>
          <lpage>70</lpage>
          <issue>11</issue>
          <volume>92</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Ilene Claudius</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Yueh-Tze Lan</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Chang</surname>
              <given-names>RK</given-names>
            </name>
            <name>
              <surname>Wetzel</surname>
              <given-names>GT</given-names>
            </name>
            <name>
              <surname>Alejos</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B30">
        <mixed-citation>30. O'Neill JO,    Mcrae AT, Troughton RW, Kenneth NG, Taylor DO, Yamani MH, et al. Brain natriuretic    peptide levels do not correlate with acute cellular rejection in de novo orthotopic    heart transplant recipients. J Heart Lung Transplant. 2005; 24 (4): 416-20.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Brain natriuretic peptide levels do not correlate with acute cellular rejection in de novo orthotopic heart transplant recipients</article-title>
          <source>J Heart Lung Transplant</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>416</fpage>
          <lpage>20</lpage>
          <issue>4</issue>
          <volume>24</volume>
          <person-group person-group-type="author">
            <name>
              <surname>O'Neill JO</surname>
            </name>
            <name>
              <surname>Mcrae</surname>
              <given-names>AT</given-names>
            </name>
            <name>
              <surname>Troughton</surname>
              <given-names>RW</given-names>
            </name>
            <name>
              <surname>Kenneth</surname>
              <given-names>NG</given-names>
            </name>
            <name>
              <surname>Taylor</surname>
              <given-names>DO</given-names>
            </name>
            <name>
              <surname>Yamani</surname>
              <given-names>MH</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B31">
        <mixed-citation>31. Hammerer-Lercher    A, Mair J, Antretter H, Ruttmann E, Poeltzl G, Laufer G, et al. B-type natriuretic    peptide as a marker of allograft rejection after heart transplantation. J Heart    Lung Transplant. 2005; 24 (9): 1444-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>B-type natriuretic peptide as a marker of allograft rejection after heart transplantation</article-title>
          <source>J Heart Lung Transplant</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>1444</fpage>
          <lpage>7</lpage>
          <issue>9</issue>
          <volume>24</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Hammerer-Lercher</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Mair</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Antretter</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Ruttmann</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Poeltzl</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Laufer</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B32">
        <mixed-citation>32. Akioka K, Takeuchi    K, Yanagi S, Hirota K, Sakamoto K, Yoshimura T, et al. Prognostic value of Doppler    transmitral flow patterns and cardiac natriuretic peptides in patients with    chronic congestive heart failure admitted for episodes of acute descompensation.    Heart Vessels. 2000; 15 (2): 53-60.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Prognostic value of Doppler transmitral flow patterns and cardiac natriuretic peptides in patients with chronic congestive heart failure admitted for episodes of acute descompensation</article-title>
          <source>Heart Vessels</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>53</fpage>
          <lpage>60</lpage>
          <issue>2</issue>
          <volume>15</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Akioka</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Takeuchi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Yanagi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Hirota</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Sakamoto</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Yoshimura</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B33">
        <mixed-citation>33. Mehra MR, Uber    WE, Park MH, Scott RL. Anything but a biopsy: monitoring for cardiac allograft    rejection. Curr Opin Cardiol. 2002; 17: 131-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Anything but a biopsy: monitoring for cardiac allograft rejection</article-title>
          <source>Curr Opin Cardiol</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>131</fpage>
          <lpage>6</lpage>
          <volume>17</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Mehra</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Uber</surname>
              <given-names>WE</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>MH</given-names>
            </name>
            <name>
              <surname>Scott</surname>
              <given-names>RL</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B34">
        <mixed-citation>34. Wagner K, Oliver    MC, Boyle GJ, Miller SA, Law YM, Pigula F, et al. Endomyocardial biopsy in pediatric    heart transplantation: a useful exercise (analysis of 1169 biopsies). Pediatric    Transplant. 2000; 4: 186-92.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Endomyocardial biopsy in pediatric heart transplantation: a useful exercise (analysis of 1169 biopsies)</article-title>
          <source>Pediatric Transplant</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>186</fpage>
          <lpage>92</lpage>
          <volume>4</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Wagner</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Oliver</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Boyle</surname>
              <given-names>GJ</given-names>
            </name>
            <name>
              <surname>Miller</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Law</surname>
              <given-names>YM</given-names>
            </name>
            <name>
              <surname>Pigula</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B35">
        <mixed-citation>35. Stehlik J,    Starling RC, Movsesian MA, Fang JC, Brown RN, Hess MI, et al. Utility of long    term surveillance endomyocardial biopsy: a multi-institutional analysis. J Heart    Lung Transplant. 2006; 25: 1402-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Utility of long term surveillance endomyocardial biopsy: a multi-institutional analysis</article-title>
          <source>J Heart Lung Transplant</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>1402</fpage>
          <lpage>9</lpage>
          <volume>25</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Stehlik</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Starling</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>Movsesian</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Fang</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>RN</given-names>
            </name>
            <name>
              <surname>Hess</surname>
              <given-names>MI</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article article-type="translation" id="TRes" xml:lang="es">
    <front-stub>
      <article-categories/>
      <title-group>
        <article-title xml:lang="es">Evaluaci&#243;n del p&#233;ptido natriur&#233;tico tipo B en el diagn&#243;stico de rechazo tras transplante cardiaco pedi&#225;trico</article-title>
      </title-group>
      <abstract xml:lang="es">
        <p>FUNDAMENTO: El rechazo constituye una de las principales causas de mortalidad tras el transplante cardiaco pedi&#225;trico. El p&#233;ptido natriur&#233;tico tipo B (BNP) ha sido estudiado como m&#233;todo en el diagn&#243;stico de rechazo agudo, sobre todo en pacientes adultos sometidos a transplante cardiaco. OBJETIVO:Correlacionar el nivel s&#233;rico de BNP al rechazo agudo diagnosticado por biopsia endomioc&#225;rdica en pacientes del grupo de transplante cardiaco pedi&#225;trico. M&#201;TODOS:Se recolectaron 50 muestras de BNP de 33 ni&#241;os en postoperatorio de transplante cardiaco, y se analizaron datos como edad, sexo, color, grupo sangu&#237;neo, cuadro inmunol&#243;gico, tiempo de evoluci&#243;n tras el transplante, clase funcional, inmunosupresi&#243;n utilizada y n&#250;mero de rechazos. RESULTADOS:Se seleccionaron a 33 ni&#241;os con edad promedio de 10,13 a&#241;os, predominio del sexo femenino (54%) y de color blanca (78%). Al momento de la dosificaci&#243;n de BNP, el tiempo promedio de transplante fue de 4,25 a&#241;os. La biopsia endomioc&#225;rdica diagnostic&#243; nueve rechazos en ocho pacientes (27%), de ellos tres presentaron grado 3A, cinco grado 2 y uno rechazo humoral. Ya al momento de la biopsia, la mayor&#237;a de los pacientes se encontraba asintom&#225;tica. El nivel s&#233;rico de BNP tuvo como promedio, 77,18 pg/ml; 144,22 pg/ml en el grupo con rechazo y 62,46 pg/ml en el grupo sin rechazo, con p = 0,02. CONCLUSI&#211;N: Ni&#241;os asintom&#225;ticos pueden presentar rechazo agudo en el postoperatorio de transplante cardiaco. El nivel s&#233;rico de BNP present&#243; diferencia estad&#237;sticamente significante en el grupo con rechazo, lo que lo convierte en posible m&#233;todo adicional en el diagn&#243;stico de rechazo cardiaco.</p>
      </abstract>
      <kwd-group xml:lang="es">
        <kwd>Transplante de coraz&#243;n</kwd>
        <kwd>rechazo del injerto</kwd>
        <kwd>p&#233;ptido natriur&#233;tico tipo B</kwd>
        <kwd>biopsia</kwd>
        <kwd>ni&#241;os</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>ART&#205;CULO ORIGINAL</bold>
      </p>
      <p>
        <fn id="top-body2">
          <label>
            <bold>Evaluaci&#243;n del p&#233;ptido natriur&#233;tico tipo B en el diagn&#243;stico de rechazo tras transplante cardiaco pedi&#225;trico</bold>
          </label>
          <p>
            <bold>Cristina de Sylos; Estela Azeka, Luis Kajita; Luis Benvenutti; C&#233;lia Cassaro Strunz; Kl&#233;bia Castello Branco; Arlindo Almeida Riso; Carla Tanamati; Marcelo Jatene; Miguel Barbero-Marcial</bold>
          </p>
        </fn>
      </p>
      <p>Instituto do Cora&#231;&#227;o (InCor) do Hospital das Cl&#237;nicas da Faculdade de Medicina Universidade de S&#227;o Paulo (HCFMUSP), S&#227;o Paulo, SP - Brasil</p>
      <p>Correspondencia</p>
      <p>
        <bold>RESUMEN</bold>
      </p>
      <p><bold>FUNDAMENTO: </bold>El rechazo constituye una de las principales causas de mortalidad tras el transplante cardiaco pedi&#225;trico. El p&#233;ptido natriur&#233;tico tipo B (BNP) ha sido estudiado como m&#233;todo en el diagn&#243;stico de rechazo agudo, sobre todo en pacientes adultos sometidos a transplante cardiaco.</p>
      <p><bold>OBJETIVO: </bold>Correlacionar el nivel s&#233;rico de BNP al rechazo agudo diagnosticado por biopsia endomioc&#225;rdica en pacientes del grupo de transplante cardiaco pedi&#225;trico.</p>
      <p><bold>M&#201;TODOS: </bold>Se recolectaron 50 muestras de BNP de 33 ni&#241;os en postoperatorio de transplante cardiaco, y se analizaron datos como edad, sexo, color, grupo sangu&#237;neo, cuadro inmunol&#243;gico, tiempo de evoluci&#243;n tras el transplante, clase funcional, inmunosupresi&#243;n utilizada y n&#250;mero de rechazos.</p>
      <p><bold>RESULTADOS: </bold>Se seleccionaron a 33 ni&#241;os con edad promedio de 10,13 a&#241;os, predominio del sexo femenino (54%) y de color blanca (78%). Al momento de la dosificaci&#243;n de BNP, el tiempo promedio de transplante fue de 4,25 a&#241;os. La biopsia endomioc&#225;rdica diagnostic&#243; nueve rechazos en ocho pacientes (27%), de ellos tres presentaron grado 3A, cinco grado 2 y uno rechazo humoral. Ya al momento de la biopsia, la mayor&#237;a de los pacientes se encontraba asintom&#225;tica. El nivel s&#233;rico de BNP tuvo como promedio, 77,18 pg/ml; 144,22 pg/ml en el grupo con rechazo y 62,46 pg/ml en el grupo sin rechazo, con p = 0,02.</p>
      <p><bold>CONCLUSI&#211;N:</bold> Ni&#241;os asintom&#225;ticos pueden presentar rechazo agudo en el postoperatorio de transplante cardiaco. El nivel s&#233;rico de BNP present&#243; diferencia estad&#237;sticamente significante en el grupo con rechazo, lo que lo convierte en posible m&#233;todo adicional en el diagn&#243;stico de rechazo cardiaco. </p>
      <p><bold>Palabras clave: </bold>Transplante de coraz&#243;n, rechazo del injerto, p&#233;ptido natriur&#233;tico tipo B, biopsia, ni&#241;os.</p>
      <p>
        <bold>Introducci&#243;n</bold>
      </p>
      <p>A pesar de los recientes avances descritos en el tratamiento de la insuficiencia cardiaca congestiva en ni&#241;os, el transplante cardiaco ha sido todav&#237;a una opci&#243;n terap&#233;utica en un gran n&#250;mero de ni&#241;os portadores de cardiopat&#237;as cong&#233;nitas complejas y cardiomiopat&#237;as refractarias, a la terap&#233;utica convencional<sup>1,2</sup>.</p>
      <p>El d&#233;cimo registro de la Sociedad Internacional de Transplante Cardiaco Pedi&#225;trico (2007)<sup>3</sup> relata que el rechazo a&#250;n se muestra una importante causa de mortalidad postransplante cardiaco pedi&#225;trico, pese a los nuevos agentes inmunosupresores y al desarrollo de nuevas estrategias para su tratamiento.</p>
      <p>El diagn&#243;stico precoz es esencial. M&#233;todos no invasivos<sup>4-6</sup> han sido investigados en ni&#241;os, ya que la biopsia endomioc&#225;rdica, aunque se la considere como m&#233;todo de elecci&#243;n, presenta limitaciones en virtud de las dificultades t&#233;cnicas, costos y complicaciones cuando realizada en ni&#241;os<sup>7-9</sup>.</p>
      <p>El nivel s&#233;rico del p&#233;ptido natriur&#233;tico tipo B (BNP) -neurohormona producida por el miocardio en respuesta a la distensi&#243;n del ventr&#237;culo o incremento de la tensi&#243;n de la pared<sup>10-12</sup>- ha sido utilizado en el transplante cardiaco, en pacientes adultos, no s&#243;lo como m&#233;todo de diagn&#243;stico de rechazo agudo<sup>13</sup>, sino tambi&#233;n como predictor de coronariopat&#237;a<sup>14-16</sup>. Pocos son los relatos acerca de la poblaci&#243;n pedi&#225;trica, con peque&#241;o n&#250;mero de pacientes y resultados controvertidos, lo que nos motiv&#243; a la realizaci&#243;n de este estudio<sup>17,18</sup>.</p>
      <p>La investigaci&#243;n consiste en evaluar el nivel s&#233;rico de BNP en comparaci&#243;n a los hallazgos histopatol&#243;gicos de la biopsia endomioc&#225;rdica, con la finalidad de diagnosticar el rechazo agudo en ni&#241;os sometidos al transplante cardiaco ortot&#243;pico.</p>
      <p>
        <bold>M&#233;todos</bold>
      </p>
      <p>Se realiz&#243; un estudio transversal en 33 pacientes en el grupo de edad pedi&#225;trico, en seguimiento tras transplante cardiaco en el Instituto do Cora&#231;&#227;o (Incor) - Hospital de Cl&#237;nicas - Facultad de Medicina de la Universidad de S&#227;o Paulo, durante el per&#237;odo comprendido entre junio de 2005 y octubre de 2006, en un total de 50 biopsias.</p>
      <p>Los criterios de inclusi&#243;n utilizados para la realizaci&#243;n del estudio son los siguientes: pacientes con m&#225;s de seis meses de evoluci&#243;n tras el transplante cardiaco, cuyos responsables estaban de acuerdo con la realizaci&#243;n del cateterismo cardiaco y del protocolo del estudio, al firmar un formulario de consentimiento.</p>
      <p>Se excluyeron a los pacientes que no realizaron cateterismo cardiaco en el per&#237;odo del estudio, as&#237; como casos en que ocurri&#243; falla en la recolecci&#243;n o almacenamiento del material.</p>
      <p>Se evaluaron los siguientes par&#225;metros cl&#237;nicos: alteraci&#243;n de humor (irritabilidad, apat&#237;a, agitaci&#243;n, somnolencia) o presencia de anorexia, fiebre, arritmia o se&#241;ales de insuficiencia cardiaca congestiva.</p>
      <p>Se recoleccionaron datos evolutivos como tiempo de evoluci&#243;n tras transplante, n&#250;mero total de episodios de rechazo, edad al momento del transplante e imunosupresi&#243;n utilizada. Adem&#225;s de estos datos, se analiz&#243; no s&#243;lo la necesidad de agentes vasoactivos y/o medicaci&#243;n anticongestiva sino tambi&#233;n la presencia de coronariopat&#237;a, insuficiencia renal o diabetes mellitus.</p>
      <p>
        <bold>Recolecci&#243;n del BNP</bold>
      </p>
      <p>Se recoleccion&#243; el BNP al momento de la biopsia endomioc&#225;rdica de los ni&#241;os sometidos a transplante cardiaco. El m&#233;todo de dosificaci&#243;n de BNP utilizado fue la prueba Triage<sup>R</sup> (Biosite Diagnostics): prueba de inmunofluorescencia para determinaci&#243;n cuantitativa del BNP en sangre o plasma conservados con EDTA como anticoagulante. Tras poner la muestra de sangre en el dispositivo, se separa el plasma por medio de un filtro. Se pone una cuantidad predeterminada de plasma en reacci&#243;n con anticuerpos fluorescentes. Tras un per&#237;odo de incubaci&#243;n, se env&#237;a la muestra para un an&#225;lisis que detecta los complejos formados con los anticuerpos fluorescentes.</p>
      <p>En este estudio se utiliz&#243; material con per&#237;odo m&#225;ximo de seis meses de recolecci&#243;n, congelado a 20&#186; Celsius negativos.</p>
      <p>
        <bold>Biopsia endomioc&#225;rdica</bold>
      </p>
      <p>Indicadas para los casos con sospecha de rechazo agudo, las biopsias se realizaron de forma consecutiva, durante la realizaci&#243;n del cateterismo anual.</p>
      <p>Para el an&#225;lisis de los datos, se dividieron a los pacientes en dos grupos: con y sin rechazo. Se evaluaron los niveles de BNP en ambos grupos. Se consider&#243; rechazo agudo celular cuando la biopsia endomioc&#225;rdica evidenci&#243; hallazgos compatibles con rechazo celular de grado igual o mayor que 2 &#243; la presencia de rechazo humoral, de acuerdo con los criterios de la Sociedad Internacional de Transplante Cardiaco y Pulmonar (ISHLT)<sup>19</sup>.</p>
      <p>
        <bold>Ecocardiograma</bold>
      </p>
      <p>Se realiz&#243; el ecocardiograma seg&#250;n las recomendaciones de la Sociedad Americana de Ecocardiograf&#237;a<sup>20</sup> con el objetivo de analizar los siguientes par&#225;metros: di&#225;metro de septo y pared en la di&#225;stole, di&#225;metro sist&#243;lico y diast&#243;lico del ventr&#237;culo izquierdo, grado de insuficiencia valvular, presencia de derrame peric&#225;rdico y se&#241;ales de disfunci&#243;n diast&#243;lica (con observaci&#243;n del flujo transmitral y an&#225;lisis del Doppler tisular en la regi&#243;n del anillo mitral). Se calcul&#243; la fracci&#243;n de eyecci&#243;n por medio del m&#233;todo de Teichholz.</p>
      <p>Se evalu&#243; la funci&#243;n diast&#243;lica por medio del flujo transvalvuvar mitral, lo cual se obtuvo a trav&#233;s de Doppler pulsado en el plano apical de cuatro c&#225;maras, para observaci&#243;n del est&#225;ndar de velocidades de las ondas mitrales E (fase de llenado r&#225;pido) y A (contracci&#243;n atrial). Se consider&#243; normal una raz&#243;n E/A mayor o igual a 1,0, mientras que se tom&#243; como alteraci&#243;n de relajaci&#243;n ventricular una raz&#243;n E/A menor que 1,0; por &#250;ltimo, se tom&#243; como est&#225;ndar restrictivo una raz&#243;n E/A mayor que 1,5.</p>
      <p>Se evalu&#243; el Doppler tisular -t&#233;cnica que indica la velocidad de movimiento del miocardio- en la regi&#243;n del anillo mitral lateral en el plano apical de cuatro c&#225;maras. Se consider&#243; anormal la inversi&#243;n del est&#225;ndar normal de las ondas E' (onda diast&#243;lica precoz) y A' (onda diast&#243;lica tard&#237;a), o sea, con E'&lt;A' o reducci&#243;n de la velocidad de la onda E'. Cuando se observ&#243; alguna alteraci&#243;n en la morfolog&#237;a o en la amplitud de ondas, se realiz&#243; un estudio en las dem&#225;s paredes de los ventr&#237;culos izquierdo y derecho.</p>
      <p>
        <bold>An&#225;lisis estad&#237;stico</bold>
      </p>
      <p>Se realiz&#243; un an&#225;lisis descriptivo de los 33 pacientes, respecto a informaciones referentes a los datos demogr&#225;ficos, cl&#237;nicos, de ex&#225;menes pre y postransplante.</p>
      <p>Se resumieron las variables cuantitativas en las medidas de tendencia central y de dispersi&#243;n (valores m&#237;nimo, m&#225;ximo, mediana, promedio y desviaci&#243;n est&#225;ndar). Se analizaron los datos cualitativos a trav&#233;s de tablas de frecuencias absolutas y relativas. Por fin, se elaboraron gr&#225;ficos con la finalidad de ilustrar estos datos.</p>
      <p>Para evaluarse las diferencias entre las concentraciones de BNP en los grupos con o sin rechazo se utiliz&#243; la prueba Mann-Whitney (no param&#233;trica). Adem&#225;s de ello, se calcularon la sensibilidad y especificidad por medio de la curva ROC para establecer como valor de corte (cut-off) el de mayor sensibilidad en la detecci&#243;n de los pacientes con rechazo agudo. Se adopt&#243; como est&#225;ndar de referencia el resultado de la biopsia.</p>
      <p>Para evaluarse comparativamente el ecocardiograma y la dosificaci&#243;n de BNP (ex&#225;menes no invasivos) con el est&#225;ndar de referencia en el diagn&#243;stico de rechazo agudo -la biopsia endomioc&#225;rdica-, se calcularon los &#237;ndices de sensibilidad y especificidad, y los valores predictivos positivo y negativo.</p>
      <p>Se interpretaron los resultados por medio del nivel de significancia (&#945;) de un 5%<sup>21,22</sup>.</p>
      <p>
        <bold>Procedimientos &#233;ticos para realizaci&#243;n de la investigaci&#243;n</bold>
      </p>
      <p>Se realiz&#243; el trabajo de acuerdo con los criterios de seguimiento para los pacientes transplantados en el InCor del Hospital de Cl&#237;nicas de FMUSP, sin acarrear ning&#250;n riesgo adicional a los pacientes involucrados en el estudio. El examen del BNP, como m&#233;todo de diagn&#243;stico y experimentaci&#243;n, no present&#243; contraindicaciones o efectos colaterales, y tampoco necesit&#243; preparaci&#243;n especial del paciente. Las medidas de recolecci&#243;n del material y de protecci&#243;n a los pacientes fueron las mismas ya practicadas por la instituci&#243;n para pacientes inmunosuprimidos, de acuerdo con las normas de la comisi&#243;n de control de infecci&#243;n hospitalaria.</p>
      <p>
        <bold>Resultados</bold>
      </p>
      <p>Se seleccionaron a 33 ni&#241;os con edad promedio de 11 a&#241;os (4 a 19 a&#241;os), con mediana de 10,13 a&#241;os y desviaci&#243;n est&#225;ndar de 4,55 a&#241;os; predominio del sexo femenino (54,5%) y de raza blanca (84,8%). Datos antropom&#233;tricos: peso de 12 a 78 kg, con mediana de 29,0 kg; estatura de 90 a 170 cm con mediana de 136,0 cm e &#237;ndice de masa corporal (IMC) con mediana de 16,35 y desviaci&#243;n est&#225;ndar de 3,78.</p>
      <p>La indicaci&#243;n de transplante cardiaco se debi&#243; al diagn&#243;stico de cardiomiopat&#237;a dilatada en 22 (67%) pacientes y cardiomiopat&#237;a restrictiva en dos (6%); cardiopat&#237;a cong&#233;nita en ocho (24%) y cardiopat&#237;a reum&#225;tica en un paciente (3%).</p>
      <p>Respecto a la distribuci&#243;n de los pacientes seg&#250;n el grupo sangu&#237;neo, 15 (45,0%) pertenec&#237;an al Grupo O y 12 (36,0%) al Grupo A; tres (9,0%), al Grupo B y otros tres (9,0%) al Grupo AB.</p>
      <p>El tiempo de evoluci&#243;n tras el transplante en el momento de la dosificaci&#243;n de BNP present&#243; mediana de 4,25 a&#241;os (seis meses a 13,6 a&#241;os). La edad promedio en el momento del transplante fue de 4,90 a&#241;os (4 meses a 15 a&#241;os).</p>
      <p>Con relaci&#243;n a la inmunosupresi&#243;n, los agentes que m&#225;s se utilizaron fueron el inhibidor de calcineurina y el micofenolato mofetil (el 78,7% y el 66,6%, respectivamente), con menor proporci&#243;n de pacientes en uso cr&#243;nico de inhibidor de calcineurina, azatioprina y corticoide. El n&#250;mero de rechazos tuvo un promedio de 3, lo que significa un valor alrededor de 1,4 rechazos por paciente.</p>
      <p>La biopsia endomioc&#225;rdica diagnostic&#243; rechazo en nueve pacientes (27%): tres con grado 3A, cinco con grado 2 y un con rechazo humoral sin se&#241;ales de rechazo celular (<xref ref-type="fig" rid="g1-body2">Gr&#225;fico 1</xref>).</p>
      <fig id="g1-body2">
        <graphic xlink:href="1678-4170-abc-92-03-0227-00011-gf01-es.jpg"/></fig>
      <p>En cuanto a la sintomatolog&#237;a, la mayor&#237;a de los pacientes se mostraba asintom&#225;tica en el momento del examen, con realizaci&#243;n del cateterismo durante el procedimiento rutinario en 36 muestras (72%). La sospecha cl&#237;nica de rechazo (alteraci&#243;n de humor, presencia de arritmia o alteraci&#243;n en el ecocardiograma) ocurri&#243; en 10 pacientes (20%), mientras que se recoleccionaron cuatro muestras (8%) como grupo control tras el tratamiento de rechazo.</p>
      <p>El nivel s&#233;rico de BNP, por su parte, mostr&#243; un promedio de 79,9 pg/ml: 144,2 pg/ml en el grupo con rechazo y 65,80 en el grupo sin rechazo, con p = 0,02 (<xref ref-type="fig" rid="g2-body2">Gr&#225;fico 2</xref>). El an&#225;lisis por curva ROC encontr&#243; 38 pg/ml como el valor de sensibilidad del 100% y especificidad del 56% para diagn&#243;stico de rechazo cardiaco, con &#225;rea de 0,74 y p 0,01 sobre la curva (<xref ref-type="fig" rid="g3-body2">Gr&#225;fico 3</xref>).</p>
      <fig id="g2-body2">
        <graphic xlink:href="1678-4170-abc-92-03-0227-00011-gf02-es.jpg"/></fig>
      <fig id="g3-body2">
        <graphic xlink:href="1678-4170-abc-92-03-0227-00011-gf03-es.jpg"/></fig>
      <p>
        <bold>Ecocardiograma</bold>
      </p>
      <p>El an&#225;lisis ecocardiogr&#225;fico (<xref ref-type="table" rid="t1-body2">tab.1</xref>) encontr&#243; alteraciones en cuatro de las nueve muestras con rechazo (44%) y en cuatro de las 41 biopsias sin rechazo (10%), con valor predictivo positivo del 50% y valor predictivo negativo del 88%. La sensibilidad del m&#233;todo fue del 44%, mientras que la especificidad result&#243; el 90% (p 0,02).</p>
      <table-wrap id="t1-body2">
        <graphic xlink:href="1678-4170-abc-92-03-0227-00011-gt01-es.jpg"/></table-wrap>
      <p>Se verificaron las siguientes alteraciones en los pacientes con rechazo: disfunci&#243;n sist&#243;lica moderada biventricular en paciente con rechazo humoral, disfunci&#243;n sist&#243;lica discreta de ventr&#237;culo izquierdo en paciente con rechazo grado 2; y en dos pacientes con grado 3A se evidenciaron insuficiencia mitral moderada y alteraciones de funci&#243;n diast&#243;lica de tipo alteraci&#243;n de relajaci&#243;n, con inversi&#243;n del est&#225;ndar de las ondas E' y A' al Doppler tisular.</p>
      <p>
        <bold>Hemodin&#225;mica</bold>
      </p>
      <p>Comparados los grupos con y sin rechazo (<xref ref-type="table" rid="t2-body2">tab.2</xref>), no se observ&#243; diferencia con relaci&#243;n a la presi&#243;n sist&#243;lica pulmonar, presi&#243;n capilar pulmonar, gasto cardiaco, resistencia vascular pulmonar o sist&#233;mica.</p>
      <table-wrap id="t2-body2">
        <graphic xlink:href="1678-4170-abc-92-03-0227-00011-gt02-es.jpg"/></table-wrap>
      <p>En lo que toca a la presencia o ausencia de coronariopat&#237;a y alteraciones del BNP, se verificaron niveles mayores que 100 pg/ml en tres de los cuatro pacientes con esta enfermedad (p=0,01).</p>
      <p>
        <bold>BNP e insuficiencia renal</bold>
      </p>
      <p>Se observ&#243; una elevaci&#243;n de los niveles de BNP no relacionado al rechazo en dos pacientes con alteraci&#243;n de la funci&#243;n renal, BNP= 208 pg/ml y 291 pg/ml, (p=0,02).</p>
      <p>
        <bold>Discusi&#243;n</bold>
      </p>
      <p>Ante a cuadros de rechazo importante en pacientes asintom&#225;ticos con posibilidad de muerte s&#250;bita, la b&#250;squeda por m&#233;todos no invasivos -con alta sensibilidad y especificidad, y que puedan tambi&#233;n repetirse de forma r&#225;pida en corto per&#237;odo de tiempo- ha ocupado gran parte de la literatura mundial acerca del transplante cardiaco.</p>
      <p>Estudios demuestran que el BNP y el NT- proBNP se revelan marcadores fidedignos en transplante e insuficiencia cardiaca, en la medida que orientan terap&#233;utica y colaboran tanto con el diagn&#243;stico como con el pron&#243;stico<sup>23,24</sup>.</p>
      <p>Una evaluaci&#243;n de la expresi&#243;n g&#233;nica de pacientes postransplante en fase cr&#243;nica -sin alteraciones hemodin&#225;micas y libres de rechazo- correlaciona el incremento s&#233;rico de BNP con genes presentes en procesos inflamatorios iniciales, remodelaci&#243;n cardiaca, activaci&#243;n inmune y alteraciones vasculares<sup>25</sup>, lo que posibilita predecir de forma precoz el desarrollo de coronariopat&#237;a o rechazo.</p>
      <p>Lan et al.<sup>26</sup>, al estudiar ni&#241;os en postoperatorio de transplante cardiaco, se&#241;alaron niveles elevados de BNP en el primer mes tras el transplante, con descenso gradual tras ese per&#237;odo, y normalizaci&#243;n de los valores (&lt; 100 pg/ml) en 14 semanas.</p>
      <p>El rechazo, como demuestra nuestro estudio, puede ocurrir en ni&#241;os de forma asintom&#225;tica en el postoperatorio de transplante cardiaco. De sea manera, la evaluaci&#243;n de los niveles s&#233;ricos de BNP puede ser un indicador precoz de ese rechazo, especialmente en sus formas m&#225;s graves como el rechazo humoral<sup>27-31</sup>.</p>
      <p>La practicidad de realizaci&#243;n del examen -ya que se puede hacerlo en el consultorio con resultado inmediato- posibilita la repetici&#243;n, ya se en casos con sospecha cl&#237;nica de rechazo, ya sea en las consultas ambulatorias de rutina. Se permite, as&#237;, postergarse la ejecuci&#243;n del cateterismo cardiaco, lo que reduce las tasas de morbidad de esos ni&#241;os.</p>
      <p>El valor encontrado en este estudio como corte para diagn&#243;stico de rechazo cardiaco agudo, evaluado por medio de curva ROC, con sensibilidad del 100%, fue de 38 pg/ml. Este dato puede ser un indicativo de que podemos tomar en cuenta valores menores y priorizar, de ese modo, la sensibilidad del m&#233;todo.</p>
      <p>A pesar de la baja sensibilidad para el diagn&#243;stico de rechazo cardiaco, el ecocardiograma es un examen de f&#225;cil ejecuci&#243;n y a la vez de alta especificidad. Nuestros hallazgos se muestran consistentes, entonces, con los que relatan Akioka et al.<sup>32</sup>. Se debe utilizar dicho examen de forma comparativa, con acceso a todos los recursos actuales disponibles, incluso el an&#225;lisis por medio del Doppler tisular. M&#225;s estudios se muestran necesarios, con la finalidad de aumentar la sensibilidad del m&#233;todo.</p>
      <p>La evaluaci&#243;n de medidas hemodin&#225;micas, excepto por la reducci&#243;n del gasto card&#237;aco, no present&#243; en este estudio correlaci&#243;n con los resultados de biopsia, datos &#233;stos concordantes con descripciones que se disponen en la literatura<sup>33-35</sup>. La correlaci&#243;n entre aumento de BNP y presencia de coronariopat&#237;a result&#243; significativa en esa muestra, hecho que evidencia la importancia del m&#233;todo tambi&#233;n como triaje de enfermedad vascular del injerto.</p>
      <p>
        <bold>Limitaciones del estudio</bold>
      </p>
      <p>El n&#250;mero limitado de pacientes y, consecuentemente, el peque&#241;o grupo con rechazo, dificult&#243; el an&#225;lisis de subgrupos.</p>
      <p>
        <bold>Implicaciones cl&#237;nicas</bold>
      </p>
      <p>El BNP se revel&#243; un examen auxiliar importante en el diagn&#243;stico de rechazo cardiaco, especialmente en los casos m&#225;s graves, como rechazo humoral.</p>
      <p>Consiste en examen de f&#225;cil ejecuci&#243;n, poco invasivo y de resultado inmediato, que puede repetirse de forma seriada, con el objetivo de postergar la realizaci&#243;n de la biopsia endomioc&#225;rdica.</p>
      <p>La correlaci&#243;n con coronariopat&#237;a tambi&#233;n demuestra la importancia del m&#233;todo en el seguimiento de largo plazo de ni&#241;os en postoperatorio tard&#237;o de transplante card&#237;aco, si se toma en cuenta que se trata de una importante causa de mortalidad tras cinco a&#241;os de transplante, que muchas veces se manifiesta con muerte s&#250;bita en pacientes ambulatorios.</p>
      <p>
        <bold>Conclusi&#243;n</bold>
      </p>
      <p>El rechazo agudo puede ocurrir de forma asintom&#225;tica en ni&#241;os en el postoperatorio tard&#237;o de transplante cardiaco y la dosificaci&#243;n del nivel s&#233;rico de BNP, realizada de forma seriada, puede auxiliar en el diagn&#243;stico de dicho rechazo.</p>
      <p>
        <bold>Potencial Conflicto de Intereses</bold>
      </p>
      <p>Declaro no haber conflicto de intereses pertinentes.</p>
      <p>
        <bold>Fuentes de Financiaci&#243;n</bold>
      </p>
      <p>El presente estudio fue parcialmente financiado por FAPESP.</p>
      <p>
        <bold>Vinculaci&#243;n Acad&#233;mica</bold>
      </p>
      <p>Este art&#237;culo forma parte de tesis de Doctorado de Cristina de Sylos, por la Facultad de Medicina de la Universidad de S&#227;o Paulo.</p>
      <p>
        <bold>Referencias</bold>
      </p>
    </body>
  </sub-article>
  <sub-article article-type="translation" id="TRen" xml:lang="en">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Articles</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="en">B-type natriuretic peptide assessment in the diagnosis of rejection after pediatric heart transplant</article-title>
      </title-group>
      <abstract xml:lang="en">
        <p>BACKGROUND: Rejection is one of the major causes of mortality following pediatric heart transplant. B-type natriuretic peptide (BNP) has been studied as a method for the diagnosis of acute rejection, especially in adult patients undergoing heart transplant. OBJECTIVE: To correlate serum BNP levels with acute rejection as diagnosed by endomyocardial biopsy in patients of the pediatric heart transplant group. METHODS: A total of 50 BNP samples were collected from 33 children in the postoperative period of heart transplant, and data on age, gender, skin color, blood group, immune panel, follow-up time after transplant, functional class, immunosuppressive regimen used and number of rejections were analyzed. RESULTS: Thirty three children with median age of 10.13 years were analyzed; of these, 54% were females and 78% were Caucasians. BNP levels were determined at a mean time from transplant of 4.25 years. Nine episodes of rejection were diagnosed in eight patients (27%) by means of endomyocardial biopsy; of these, three were grade 3A, five were grade 2, and one had humoral rejection. At the moment of biopsy, most patients were asymptomatic. The mean serum BNP level was 77.18 pg/ml, with 144.22 pg/ml in the group with rejection and 62.46 pg/ml in the group without rejection, with p = 0.02. CONCLUSION: Asymptomatic children can present acute rejection in the postoperative period of heart transplant. Serum BNP levels show a statistically significant difference in the group with rejection and thus can be an additional method in the diagnosis of cardiac rejection.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <kwd>Natriuretic peptide, B-type</kwd>
        <kwd>graft rejection</kwd>
        <kwd>heart transplantation</kwd>
        <kwd>biopsy</kwd>
        <kwd>children</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>ORIGINAL ARTICLE</bold>
      </p>
      <p>
        <fn id="top-body3">
          <label>
            <bold>B-type natriuretic peptide assessment in the diagnosis of rejection after pediatric heart transplant</bold>
          </label>
          <p>
            <bold>Cristina de Sylos; Estela Azeka; Luis Kajita; Luis Benvenutti; C&#233;lia Cassaro Strunz; Kl&#233;bia Castello Branco; Arlindo Almeida Riso; Carla Tanamati; Marcelo Jatene; Miguel Barbero-Marcial</bold>
          </p>
        </fn>
      </p>
      <p>Instituto do Cora&#231;&#227;o (InCor) do Hospital das Cl&#237;nicas da Faculdade de Medicina Universidade de S&#227;o Paulo (HCFMUSP), S&#227;o Paulo, SP - Brazil</p>
      <p>Mailing address</p>
      <p>
        <bold>SUMMARY</bold>
      </p>
      <p><bold>BACKGROUND: </bold>Rejection is one of the major causes of mortality following pediatric heart transplant. B-type natriuretic peptide (BNP) has been studied as a method for the diagnosis of acute rejection, especially in adult patients undergoing heart transplant.</p>
      <p><bold>OBJECTIVE: </bold>To correlate serum BNP levels with acute rejection as diagnosed by endomyocardial biopsy in patients of the pediatric heart transplant group.</p>
      <p><bold>METHODS: </bold>A total of 50 BNP samples were collected from 33 children in the postoperative period of heart transplant, and data on age, gender, skin color, blood group, immune panel, follow-up time after transplant, functional class, immunosuppressive regimen used and number of rejections were analyzed.</p>
      <p><bold>RESULTS: </bold>Thirty three children with median age of 10.13 years were analyzed; of these, 54% were females and 78% were Caucasians. BNP levels were determined at a mean time from transplant of 4.25 years. Nine episodes of rejection were diagnosed in eight patients (27%) by means of endomyocardial biopsy; of these, three were grade 3A, five were grade 2, and one had humoral rejection. At the moment of biopsy, most patients were asymptomatic. The mean serum BNP level was 77.18 pg/ml, with 144.22 pg/ml in the group with rejection and 62.46 pg/ml in the group without rejection, with p = 0.02.</p>
      <p><bold>CONCLUSION: </bold>Asymptomatic children can present acute rejection in the postoperative period of heart transplant. Serum BNP levels show a statistically significant difference in the group with rejection and thus can be an additional method in the diagnosis of cardiac rejection.</p>
      <p><bold>Key words:</bold>Natriuretic peptide, B-type; graft rejection; heart transplantation; biopsy; children.</p>
      <p>
        <bold>Introduction</bold>
      </p>
      <p>Despite recent advances described in the treatment of congestive heart failure in children, heart transplant remains the treatment of choice in a large number of children with complex congenital heart diseases and cardiomyopathies refractory to conventional therapy<sup>1,2</sup>.</p>
      <p>The tenth official pediatric heart transplantation report of the International Society for Heart and Lung Transplantation (2007)<sup>3</sup> reports that rejection remains a major cause of mortality after pediatric heart transplant despite the new immunosuppressive agents and the development of new therapeutic strategies.</p>
      <p>Early diagnosis is essential and noninvasive methods<sup>4-6</sup> have been investigated in children because, despite being considered the method of choice, endomyocardial biopsy has limitations concerning technical difficulties, costs and complications when performed in children<sup>7-9</sup>.</p>
      <p>Serum levels of B-type natriuretic peptide (BNP), a neurohormone produced by the myocardium in response to ventricular distension or increased wall stress<sup>10-12</sup>, have been used in heart transplant in adult patients as a diagnostic method of acute rejection<sup>13</sup> and as a predictor of coronary heart disease<sup>14-16</sup>. Few reports are available in the pediatric population, with small number of patients and controversial outcomes, and this encouraged the conduction of the present study<sup>17,18</sup>.</p>
      <p>This study consists of the assessment of serum BNP levels in comparison with pathological findings of endomyocardial biopsy, aiming at the diagnosis of acute rejection in children undergoing orthotopic heart transplant.</p>
      <p>
        <bold>Methods</bold>
      </p>
      <p>This is a cross-sectional study of 33 pediatric patients followed-up after heart transplant in <italic>Instituto do Cora&#231;&#227;o do Hospital das Cl&#237;nicas da Faculdade de Medicina da Universidade de S&#227;o Paulo</italic>, between June 2005 and October 2006; a total of 50 biopsies were performed.</p>
      <p>The inclusion criteria for participation in the study were: patients with a longer than six-month follow-up after heart transplant, whose guardians agreed on the performance of cardiac catheterization and of the study protocol and gave their informed consent.</p>
      <p>Patients not undergoing cardiac catheterization during the study period and cases with flaws in specimen collection or storage were excluded.</p>
      <p>The clinical parameters assessed were: mood change (irritability, apathy, agitation, sleepiness) or presence of anorexia, fever, arrhythmia or signs of congestive heart failure.</p>
      <p>Outcome data such as follow-up time after transplant, total number of rejection episodes, age at transplant, immunossupressive regimen used, need for vasoactive agents and/or anticongestive medication, as well as the presence of coronary heart disease, renal failure or diabetes mellitus were collected.</p>
      <p>
        <bold>BNP sample collection</bold>
      </p>
      <p>Blood sample for BNP determination was collected at the moment of endomyocardial biopsy of children undergoing heart transplant. The method used for BNP determination was the Triage<sup>TM</sup> test (Biosite Diagnostics), an immunofluorescence test for the quantitative BNP determination in blood or plasma preserved with EDTA as the anticoagulant. The sample is placed in the device, and then plasma is separated from blood by a filter. A predetermined amount of plasma is put to react with fluorescent antibodies. After an incubation period, the sample is sent to analysis for detection of the complexes formed with fluorescent antibodies.</p>
      <p>In this study, the specimens used had been collected six months before at most, and kept frozen at minus 20&#186;C.</p>
      <p>
        <bold>Endomyocardial biopsy</bold>
      </p>
      <p>Biopsies were performed consecutively during the annual catheterization and were indicated in the cases in which acute rejection was suspected.</p>
      <p>For data analysis, patients were divided into two groups (with rejection and without rejection) and BNP levels were evaluated in both groups. Acute cellular rejection was considered when endomyocardial biopsy findings were consistent with cellular rejection equal to or greater than grade 2 or with the presence of humoral rejection, according to the International Society for Heart and Lung Transplantation (ISHLT)'s criteria<sup>19</sup>.</p>
      <p>
        <bold>Echocardiography</bold>
      </p>
      <p>Echocardiography was performed according to the American Society of Echocardiography's recommendations<sup>20</sup> and was aimed at analyzing the following parameters: diastolic septal and wall diameter, left ventricular systolic and diastolic diameters, degree of valve regurgitation, presence of pericardial effusion, and signs of diastolic dysfunction (with transmitral flow and tissue Doppler analysis made at the mitral annulus). Ejection fraction was calculated using the Teichholz method.</p>
      <p>Diastolic function was assessed using transmitral flow as obtained by pulsed Doppler in the four-chamber apical view, and the velocity patterns of the mitral E wave (rapid filling phase) and A wave (atrial contraction) were observed. E/A ratios equal to or greater than 1.0 were considered normal; E/A ratios lower than 1.0 were considered as ventricular relaxation abnormality; and E/A ratios greater than 1.5 were considered as restrictive pattern.</p>
      <p>Tissue Doppler, a technique that evaluates the velocity of myocardial motion, was assessed at the lateral mitral annulus in the four-chamber apical view. Inversion of the normal E' wave (early diastolic wave) and A' wave (late diastolic wave) pattern with E'&lt;A' or reduction of E' wave velocity was considered abnormal. Whenever any change in wave morphology or amplitude was observed, the other left ventricular and right ventricular walls were also studied.</p>
      <p>
        <bold>Statistical analysis</bold>
      </p>
      <p>Descriptive analysis was conducted regarding demographic, clinical, and pre and post-transplant data of the 33 patients.</p>
      <p>The quantitative variables were summarized by the measures of central tendency and dispersion (minimum, maximum, median, and mean values, as well as standard deviation). Qualitative data were analyzed using absolute and relative frequency tables. Graphs were plotted in order to illustrate the data.</p>
      <p>The Mann-Whitney (non-parametric) test was used to analyze the differences between BNP concentrations in the groups with and without rejection. Also, sensitivity and specificity were calculated using the ROC curve to establish the cut-off point at the highest sensitivity value for the detection of patients with acute rejection, adopting biopsy findings as the reference standard.</p>
      <p>Sensitivity and specificity indexes, positive predictive value and negative predictive value were calculated for the comparative analysis of echocardiogram and BNP levels (noninvasive tests) with the reference standard (endomyocardial biopsy).</p>
      <p>The results were interpreted with the significance level (&#945;) set at 5%<sup>21,22</sup>.</p>
      <p>
        <bold>Ethical procedures for conducting the research</bold>
      </p>
      <p>The study was conducted according to the follow-up criteria for patients transplanted in <italic>Instituto do Cora&#231;&#227;o (InCor) do Hospital das Cl&#237;nicas da FMUSP</italic> and did not pose any additional risk to the study participants. BNP test, as a diagnostic and experimental method, did not show any contraindications or side effects, nor did it require any special patient preparation. Measures for specimen collection and patient protection were the same adopted in the institution for immunosuppressed patients according to standards of the commission on hospital infection control.</p>
      <p>
        <bold>Results</bold>
      </p>
      <p>A total of 33 children with mean age of 11 years (4 to 19 years), median age of 10.13 and standard deviation of 4.55 years were studied. There was a predominance of the female gender (54.5%) and Caucasians (84.8%). Anthropometric data: weight from 12 to 78 kg, with median of 29.0 kg; height from 90 to 170 cm, with median of 136.0 cm; and median body mass index (BMI) of 16.35 and standard deviation of 3.78.</p>
      <p>Heart transplant was indicated for dilated cardiomyopathy in 22 (67%) patients, restrictive cardiomyopathy in two (6%), congenital heart disease in eight (24%), and rheumatic heart disease in one patient (3%).</p>
      <p>Regarding patient distribution according to blood group, 15 (45.0%) were from group O; 12 (36.0%) from group A; three (9.0%) from group B; and three (9.0%) from group AB.</p>
      <p>The median follow-up time after transplant at the moment of BNP determination was 4.25 years (from six months to 13.6 years). The mean age at the moment of transplant was 4.90 years (from four months to 15 years).</p>
      <p>In relation to immunosuppression, calcineurin inhibitor and mycophenolate mofetil were the most frequently used agents (78.7% and 66.6%, respectively). A smaller proportion of patients were on chronic calcineurin inhibitor and azathioprine and corticosteroid. The mean number of rejections was 3&#177;1.4 rejections per patient.</p>
      <p>By means of endomyocardial biopsy, rejection was diagnosed in nine patients (27%), of whom three had grade 3A, five had grade 2, and one had humoral rejection with no signs of cellular rejection (<xref ref-type="fig" rid="g1-body3">Graph 1</xref>).</p>
      <fig id="g1-body3">
        <graphic xlink:href="1678-4170-abc-92-03-0227-00011-gf01-en.jpg"/></fig>
      <p>In relation to the symptoms, most of the patients were asymptomatic at the moment of the test, and catheterization was performed during a routine procedure in 36 samples (72%). Rejection was clinically suspected (mood change, presence of arrhythmia or abnormal echocardiogram) in 10 patients (20%), and four samples (8%) were collected as controls after treatment of rejection.</p>
      <p>The mean serum BNP level was 79.9 pg/mL, with 144.2 pg/mL in the group with rejection and 65.80 in the group without rejection, p = 0.02 (<xref ref-type="fig" rid="g2-body3">Graph 2</xref>). The analysis of the ROC curve showed 38 pg/mL as the value at a 100% sensitivity and 56% specificity for the diagnosis of cardiac rejection, with an area under the curve of 0.74 and p = 0.01 (<xref ref-type="fig" rid="g3-body3">Graph 3</xref>).</p>
      <fig id="g2-body3">
        <graphic xlink:href="1678-4170-abc-92-03-0227-00011-gf02-en.jpg"/></fig>
      <fig id="g3-body3">
        <graphic xlink:href="1678-4170-abc-92-03-0227-00011-gf03-en.jpg"/></fig>
      <p>
        <bold>Echocardiography</bold>
      </p>
      <p>Echocardiographic analysis (<xref ref-type="table" rid="t1-body3">Table 1</xref>) found abnormalities in four out of the nine samples with rejection (44%), and in four of the 41 biopsies without rejection (10%), with a 50% positive predictive value and 88% negative predictive value. The sensitivity of the method was 44% and the specificity was 90% (p = 0.02).</p>
      <table-wrap id="t1-body3">
        <graphic xlink:href="1678-4170-abc-92-03-0227-00011-gt01-en.jpg"/></table-wrap>
      <p>The abnormalities found in patients with rejection were: moderate biventricular systolic dysfunction in a patient with humoral rejection; mild left ventricular systolic dysfunction in a patient with grade-2 rejection; and moderate mitral regurgitation and diastolic dysfunction with relaxation abnormality with E' and A' wave pattern inversion on tissue Doppler in two patients with grade-3 rejection, respectively.</p>
      <p>
        <bold>Hemodynamics</bold>
      </p>
      <p>In the comparison of the groups with and without rejection (<xref ref-type="table" rid="t2-body3">Table 2</xref>), no difference was observed in relation to pulmonary systolic pressure, pulmonary capillary pressure, cardiac output, or pulmonary or systemic vascular resistance.</p>
      <table-wrap id="t2-body3">
        <graphic xlink:href="1678-4170-abc-92-03-0227-00011-gt02-en.jpg"/></table-wrap>
      <p>In relation to the presence or absence of coronary heart disease and abnormal BNP values, greater than 100 pg/mL levels were observed in three of the four patients with coronary heart disease (p = 0.01).</p>
      <p>
        <bold>BNP and renal failure</bold>
      </p>
      <p>Increased BNP levels not related to rejection were observed in two patients with abnormal renal function, with BNP= 208 pg/mL and 291 pg/mL, (p=0.02).</p>
      <p>
        <bold>Discussion</bold>
      </p>
      <p>In light of significant manifestations of rejection in asymptomatic patients that could lead to sudden death, non-invasive, high-sensitivity and specificity methods that could be repeated rapidly and in short time intervals have been the focus of a great part of the literature on heart transplant worldwide.</p>
      <p>Studies have demonstrated BNP and NT-proBNP as reliable markers in heart failure and transplant, guiding treatment and helping in the diagnosis and prognosis<sup>23,24</sup>.</p>
      <p>Assessment of gene expression of post-transplant patients in the chronic phase with no hemodynamic changes and free from rejection correlates increased serum BNP levels with genes present in initial inflammatory processes, cardiac remodeling, immune activation and vascular changes<sup>25</sup>, permitting an early prediction of the development of coronary heart disease or rejection .</p>
      <p>Lan et al<sup>26</sup> studied children in the post-operative period of heart transplant and observed that BNP levels were high in the first post-transplant month and declined gradually after this period, returning to normal values (&lt; 100 pg/mL) in 14 weeks.</p>
      <p>As demonstrated in the present study, acute rejection may be asymptomatic in children in the postoperative period of heart transplant, and the evaluation of serum BNP levels may be an early indicator of this rejection, especially in the most severe forms such as humoral rejection<sup>27-31</sup>.</p>
      <p>The test is easy to perform, and can be done in the medical office with immediate result, so it can be repeated in cases in which rejection is suspected or even in routine outpatient visits. This permits cardiac catheterization to be postponed, which reduces morbidity rates among these children.</p>
      <p>The cut-off point found in this study for the diagnosis of acute cardiac rejection using the ROC curve with 100% sensitivity was 38 pg/mL. This can indicate that lower values could be considered, prioritizing the sensitivity of the method.</p>
      <p>Despite its low sensitivity for the diagnosis of cardiac rejection, echocardiography is easy to perform and has a high specificity, findings that are consistent with those reported by Akioka et al<sup>32</sup>. It should be used comparatively and along with all the resources currently available, including tissue-Doppler analysis. Further studies are necessary to increase the sensitivity of the method.</p>
      <p>The assessment of hemodynamic measurements, except for reduced cardiac output, did not correlate with biopsy findings in this study, in corroboration with other studies of the literature<sup>33-35</sup>. The correlation between increased BNP levels and the presence of coronary heart disease was significant in this sample, thus showing the importance of the method in the screening of graft vascular disease as well.</p>
      <p>
        <bold>Study limitations</bold>
      </p>
      <p>The small number of patients, and consequently the small group with rejection, made analysis of subgroups difficult.</p>
      <p>
        <bold>Clinical implications</bold>
      </p>
      <p>BNP proved to be an important ancillary test in the diagnosis of cardiac rejection, especially in the most severe cases, such as those with humoral rejection.</p>
      <p>This test is easy to perform, only slightly invasive, allows immediate result, and can be repeated serially in order to postpone endomyocardial biopsy.</p>
      <p>Its correlation with coronary heart disease also points out the importance of the method in the long-term follow-up of children in the late postoperative period of heart transplant, considering that this is an important cause of mortality after five years of transplant, and is frequently manifested as sudden death in outpatients.</p>
      <p>
        <bold>Conclusion</bold>
      </p>
      <p>Acute rejection can be asymptomatic in the late postoperative period of heart transplant children, and serial serum BNP level determination may help the diagnosis of this rejection.</p>
      <p>
        <bold>Potential Conflict of Interest</bold>
      </p>
      <p>No potential conflict of interest relevant to this article was reported.</p>
      <p>
        <bold>Sources of Funding</bold>
      </p>
      <p>This study was partially funded by FAPESP.</p>
      <p>
        <bold>Study Association</bold>
      </p>
      <p>This article is part of the thesis of Doctoral submitted by Cristina de Sylos, from Faculdade de Medicina da Universidade de S&#227;o Paulo.</p>
      <p>
        <bold>References</bold>
      </p>
    </body>
  </sub-article>
</article>
